US.LLY · Lilly (Eli)

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.5,
      "details": {
        "atrPct": 3.4133804516984516,
        "turnoverUsdM": 1863.3493016095497,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.LLY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 1136.9744,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 6.8,
      "take_profit_price": 1320.5244,
      "target_multiplier": 1.9,
      "technical_strength": 1.9,
      "take_profit_percent": 8.2
    },
    "positionPoints": 1.5,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2011552940018437,
    "stopLossPercent": 6.826760903396903,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 72.2,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.2,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 11
  },
  "market": {
    "ma20": 1179.9655,
    "ma50": 1164.6152,
    "close": 1220.28,
    "prevClose": 1215.02,
    "avgVolume20": 2711754,
    "volumeRatio": 0.56,
    "changePercent": 0.43
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 11,
    "details": {
      "ret_5d": 0.043099208820706725,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 11,
      "vcp_bonus": 0,
      "vol_ratio": 0.5526517228462386,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 0.9137271657282222,
      "volat_points": 0,
      "day_range_pct": 0.029026160495308578,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 72.2,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 9.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 62.67,
        "contribution": 9.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 67,
        "contribution": 6.7
      },
      {
        "raw": 22.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 73.67,
        "contribution": 22.1
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 61.2,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 9.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.7/10分",
      "技術信號分析總分: 22.1/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 10,
      "市場環境": 9.4,
      "情緒分析": 6,
      "技術信號": 22.1,
      "風險管理": 6.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 1863.3493016095497,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 1.6,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.LLY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 701.0319982000001,
                "ma50": 713.49480132,
                "name": "QQQ",
                "close": 723.70001,
                "points": 1.4
              },
              "spy": {
                "ma20": 753.1860015999998,
                "ma50": 748.1182043399999,
                "name": "SPY",
                "close": 772.48999,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.4133804516984516,
          "atrPoints": 2,
          "cciPoints": 4,
          "vixPoints": 0,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141192658,
                "url": "https://finnhub.io/api/news?id=ab20d3fac01fdbbb49072572815454939c62922e0f8a3cfd272eecffef68e391",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) shows a strong technical breakout setup with a 10/10 rating, tight consolidation, and defined support/resistance levels.",
                "category": "company",
                "datetime": 1786537892,
                "headline": "Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup"
              },
              {
                "id": 141180188,
                "url": "https://finnhub.io/api/news?id=baea52fabf204935a8f4bb8bf7fb277278893936d61b8f8794dc12b183169bed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly’s updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay updated as...",
                "category": "company",
                "datetime": 1786404051,
                "headline": "Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions"
              },
              {
                "id": 141180189,
                "url": "https://finnhub.io/api/news?id=328cfb139ab5465f3851efd62dfbb11509b58513062093c5cf9c4e71670002a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.",
                "category": "company",
                "datetime": 1786402912,
                "headline": "What Analysts Really Pressed LLY On This Quarter"
              },
              {
                "id": 141177536,
                "url": "https://finnhub.io/api/news?id=06f9855d2799e576a4ddc346eaf2e110f1bc1ef8bcee92747cb4ca2cb44668bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]",
                "category": "company",
                "datetime": 1786385250,
                "headline": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY"
              },
              {
                "id": 141173843,
                "url": "https://finnhub.io/api/news?id=3cf21eb0d3798ce8a5f36093feaffef73215e072469618ccda4e38d901fd3569",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) passes high-growth momentum screen with strong earnings, sales acceleration, and technical setup. See why LLY scores well.",
                "category": "company",
                "datetime": 1786363903,
                "headline": "Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup"
              },
              {
                "id": 141165590,
                "url": "https://finnhub.io/api/news?id=04feb778c0bf43bc03b43f2a84b0a57a91dec9c1b9b10d9afc4fa15db7c8c132",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused […]",
                "category": "company",
                "datetime": 1786265471,
                "headline": "Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook"
              },
              {
                "id": 141161626,
                "url": "https://finnhub.io/api/news?id=94e314bfd9ee20f7d2be96fab6b4b9b69110d4aad692ce524f8414c943ae4615",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786224322,
                "headline": "LLY Q2 Deep Dive: Key Products and Pipeline Expansion"
              },
              {
                "id": 141161627,
                "url": "https://finnhub.io/api/news?id=7c72d5fbd38d1f0103244abf3dc7f6e8ad5ef62240f2009328ec1b2dc3454ceb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portfolio beyond its diabetes and obesity...",
                "category": "company",
                "datetime": 1786223772,
                "headline": "Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens"
              }
            ],
            "raw_source": [
              {
                "id": 141192658,
                "url": "https://finnhub.io/api/news?id=ab20d3fac01fdbbb49072572815454939c62922e0f8a3cfd272eecffef68e391",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) shows a strong technical breakout setup with a 10/10 rating, tight consolidation, and defined support/resistance levels.",
                "category": "company",
                "datetime": 1786537892,
                "headline": "Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup"
              },
              {
                "id": 141193636,
                "url": "https://finnhub.io/api/news?id=7bfc4b9332d97a09de7dfbe3cb43cc3e1d4b127d00f25ae64f7b45081dc0433c",
                "image": "",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1786536901,
                "headline": "I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)"
              },
              {
                "id": 141195185,
                "url": "https://finnhub.io/api/news?id=74fc4253cb1300007f3b3a3e8fc709b87c799a119423afd9f0d478a8546069a2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/12/Eli-Lilly.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.",
                "category": "company",
                "datetime": 1786534442,
                "headline": "Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities"
              },
              {
                "id": 141185209,
                "url": "https://finnhub.io/api/news?id=512cb5e3c45f8dd23e0f741191a2f85925d30cb818018ad7e2e80ee8846b5488",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205618145/image_2205618145.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "U.S. equity markets rebounded strongly this week, with gains led by technology and growth-oriented sectors.",
                "category": "company",
                "datetime": 1786448940,
                "headline": "ValuEngine Weekly Market Summary And Commentary"
              },
              {
                "id": 141185818,
                "url": "https://finnhub.io/api/news?id=19dbe250bd1d79cfa3fff53b2c0b0c01f22356f877e7370c084578f6b31f2d53",
                "image": "https://image.cnbcfm.com/api/v1/image/108345367-1785944365993-gettyimages-2275860755-64393_48_mso6316.jpeg?v=1785944445&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.",
                "category": "company",
                "datetime": 1786426036,
                "headline": "Eli Lilly takes weight-loss pill battle global with first Foundayo approval in Europe"
              },
              {
                "id": 141182419,
                "url": "https://finnhub.io/api/news?id=3cfddac43682cfffff44b82c34297fce10d120b46260a0196bdcb437835a12c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Jeff Marks and Jim Cramer say Eli Lilly's GLP-1 stock rally has years left, backed by surging global demand.",
                "category": "company",
                "datetime": 1786421580,
                "headline": "Cramer’s Analyst Says Eli Lilly’s GLP-1 Stock Rally Has Years Left to Run"
              },
              {
                "id": 141180188,
                "url": "https://finnhub.io/api/news?id=baea52fabf204935a8f4bb8bf7fb277278893936d61b8f8794dc12b183169bed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly’s updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay updated as...",
                "category": "company",
                "datetime": 1786404051,
                "headline": "Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions"
              },
              {
                "id": 141180189,
                "url": "https://finnhub.io/api/news?id=328cfb139ab5465f3851efd62dfbb11509b58513062093c5cf9c4e71670002a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.",
                "category": "company",
                "datetime": 1786402912,
                "headline": "What Analysts Really Pressed LLY On This Quarter"
              },
              {
                "id": 141180190,
                "url": "https://finnhub.io/api/news?id=df60c7878a3ae64e9cb7d17c11ecff333ed81f09cff693ce240fdd2ae0fe4af6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of […]",
                "category": "company",
                "datetime": 1786400518,
                "headline": "Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?"
              },
              {
                "id": 141180163,
                "url": "https://finnhub.io/api/news?id=1b20b16bf3903a3bc838753299ce5d5cc0843dc731e2a86b650151efa21cafb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "One of its more popular products just got the green light from a major national regulator.",
                "category": "company",
                "datetime": 1786400032,
                "headline": "Why Eli Lilly Topped the Market Today"
              },
              {
                "id": 141178835,
                "url": "https://finnhub.io/api/news?id=0082e11ca1611158dc651352dbc1780da6dc5554a0af2e5a296724e082585aae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets. Yet another competitive advantage for investors to […]",
                "category": "company",
                "datetime": 1786397963,
                "headline": "Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?"
              },
              {
                "id": 141178836,
                "url": "https://finnhub.io/api/news?id=4c28520f689c26181a43865881444b641b3ecc602645653667377b4a6e0fea30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and th",
                "category": "company",
                "datetime": 1786391884,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 141177534,
                "url": "https://finnhub.io/api/news?id=b82fe9431cd407ceb26d85a6af222081880af00e00e913ed7f4ad58baf055b21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Foundayo secured its first European authorization, extending Lilly's obesity portfolio beyond injectable medicines",
                "category": "company",
                "datetime": 1786390507,
                "headline": "Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill"
              },
              {
                "id": 141179899,
                "url": "https://finnhub.io/api/news?id=7ceda054cbf1a9731f12135ecf892bed93b994a2553ae0995829b82575cad1ad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233342016/image_2233342016.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi deals. Click for this RXRX update.",
                "category": "company",
                "datetime": 1786389747,
                "headline": "Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News"
              },
              {
                "id": 141177536,
                "url": "https://finnhub.io/api/news?id=06f9855d2799e576a4ddc346eaf2e110f1bc1ef8bcee92747cb4ca2cb44668bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]",
                "category": "company",
                "datetime": 1786385250,
                "headline": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY"
              },
              {
                "id": 141176601,
                "url": "https://finnhub.io/api/news?id=66a9761e06dd6273f6d7d67ab03fb9e01f47f3d95fee99cdac4419ac59404e4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State",
                "category": "company",
                "datetime": 1786383631,
                "headline": "Sector Update: Healthcare Stocks Rise in Afternoon Trading"
              },
              {
                "id": 141177535,
                "url": "https://finnhub.io/api/news?id=78a8ecda52c573a5577b49c9d195eb371252eb8e0decd94bb0da891e00e0c7c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The U.K.’s Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and maintenance in adults with obesity, as well as certain overweight adults with at least one weight-related health condition.",
                "category": "company",
                "datetime": 1786383062,
                "headline": "Eli Lilly’s GLP-1 Pill Secures First European Milestone – Here’s Everything To Know About UK MHRA’s Foundayo Approval"
              },
              {
                "id": 141176602,
                "url": "https://finnhub.io/api/news?id=9619ef377aa37b3295cafc7d2a4686061b76f5c87f4c8df7da46959859930693",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.",
                "category": "company",
                "datetime": 1786377692,
                "headline": "Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection"
              },
              {
                "id": 141176603,
                "url": "https://finnhub.io/api/news?id=440232f699eac4ad4b8d7158f42d572e7aa32c4f24498573871c53c5c55903b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.",
                "category": "company",
                "datetime": 1786376460,
                "headline": "Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?"
              },
              {
                "id": 141181013,
                "url": "https://finnhub.io/api/news?id=128c22f0655c11d7628303df517120935116e20508946aae3c87428e9be76980",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Global biopharmaceutical company Bristol Myers Squibb will establish a new pharmaceutical manufacturing campus near Houston, bringing nearly 500 jobs, the governor's office says.",
                "category": "company",
                "datetime": 1786374322,
                "headline": "Bristol Myers Squibb opening pharmaceutical manufacturing campus near Houston"
              },
              {
                "id": 141175245,
                "url": "https://finnhub.io/api/news?id=a973147764263f3bdc864ad125bd056f1b6a36b2ab0a6f63d654ad0875da6be9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.",
                "category": "company",
                "datetime": 1786371120,
                "headline": "This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News."
              },
              {
                "id": 141175244,
                "url": "https://finnhub.io/api/news?id=545abec5cbb403d32508561d27a8df78a3ee6ccc31fa4690e52788a587f768f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s (\"Remedium\") $10 million Series A financing and has completed the round's initial closing, with participation from Eli Lilly and Company (\"Lilly\") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors.",
                "category": "company",
                "datetime": 1786370400,
                "headline": "Lifespan Vision Ventures Leads Remedium Bio's Series A Financing"
              },
              {
                "id": 141176307,
                "url": "https://finnhub.io/api/news?id=d21e501076bab3f994c16ea1ef24b084101ad446fcc13a1c459d5de2c6ed9ec7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2272442557/image_2272442557.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "The recent increasing adoption of GLP-1 drugs has fundamentally changed the landscape of weight loss and health habits.",
                "category": "company",
                "datetime": 1786368900,
                "headline": "Weight-Loss Drugs - How Are GLP-1s Redistributing Consumer Spending?"
              },
              {
                "id": 141175246,
                "url": "https://finnhub.io/api/news?id=591f1c66fd898da59a3ead793f279e37e93678deb7ec350180d0680a1f8e0997",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.",
                "category": "company",
                "datetime": 1786367820,
                "headline": "Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock"
              },
              {
                "id": 141173843,
                "url": "https://finnhub.io/api/news?id=3cf21eb0d3798ce8a5f36093feaffef73215e072469618ccda4e38d901fd3569",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) passes high-growth momentum screen with strong earnings, sales acceleration, and technical setup. See why LLY scores well.",
                "category": "company",
                "datetime": 1786363903,
                "headline": "Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup"
              },
              {
                "id": 141173839,
                "url": "https://finnhub.io/api/news?id=cdede5a86a1a9c715bcc2916ec012ef4f51f2e1958b7fa818b04daf0ff357e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.",
                "category": "company",
                "datetime": 1786363255,
                "headline": "3 Beaten-Down Healthcare Stocks to Buy in August"
              },
              {
                "id": 141172163,
                "url": "https://finnhub.io/api/news?id=9356fed22ce295de843eda2daed53d41ab188e37f0a92398a2848a1d1d986204",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now.",
                "category": "company",
                "datetime": 1786338000,
                "headline": "Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs"
              },
              {
                "id": 141171515,
                "url": "https://finnhub.io/api/news?id=94d82dbdbb2621fa343f905b14fe0424c0b1ea9ae83a9c6b0f3d10e720e2dcad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Amazon.com Inc.‘s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced on Thursday that the service would automate eligibility checks, prior authorizations, and billing,...",
                "category": "company",
                "datetime": 1786325468,
                "headline": "Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients"
              },
              {
                "id": 141165590,
                "url": "https://finnhub.io/api/news?id=04feb778c0bf43bc03b43f2a84b0a57a91dec9c1b9b10d9afc4fa15db7c8c132",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused […]",
                "category": "company",
                "datetime": 1786265471,
                "headline": "Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook"
              },
              {
                "id": 141164828,
                "url": "https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.",
                "category": "company",
                "datetime": 1786243803,
                "headline": "Top 50 High-Quality Dividend Growth Stocks For August 2026"
              },
              {
                "id": 141161584,
                "url": "https://finnhub.io/api/news?id=6a0988391faa72f1b2fee86fd03253c035c8beb825cd21d92ded5ecf8998a2d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Hedge fund Situational Awareness is forced to sell its equity holdings, leading to a drop and a pop in AI-related stocks. What went wrong?",
                "category": "company",
                "datetime": 1786225537,
                "headline": "When Leverage Goes Wrong on Wall Street"
              },
              {
                "id": 141161626,
                "url": "https://finnhub.io/api/news?id=94e314bfd9ee20f7d2be96fab6b4b9b69110d4aad692ce524f8414c943ae4615",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786224322,
                "headline": "LLY Q2 Deep Dive: Key Products and Pipeline Expansion"
              },
              {
                "id": 141161627,
                "url": "https://finnhub.io/api/news?id=7c72d5fbd38d1f0103244abf3dc7f6e8ad5ef62240f2009328ec1b2dc3454ceb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portfolio beyond its diabetes and obesity...",
                "category": "company",
                "datetime": 1786223772,
                "headline": "Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens"
              },
              {
                "id": 141160660,
                "url": "https://finnhub.io/api/news?id=660ae6a5fba8ae4a565df26d348846c1f256aac28066aa0e4dccd016185b45da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "It's not much of a rivalry yet.",
                "category": "company",
                "datetime": 1786218600,
                "headline": "Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?"
              },
              {
                "id": 141160682,
                "url": "https://finnhub.io/api/news?id=946adcc78cc6c8c6ec3e13d4268d539e825b96e3ecfcfa238902291680736f80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came ...",
                "category": "company",
                "datetime": 1786213980,
                "headline": "BofA points to the Eli Lilly market that could outsize the U.S."
              },
              {
                "id": 141159807,
                "url": "https://finnhub.io/api/news?id=0aa39304f97c90312a613429dbc4525e638241262c46bb0252f1ab8bb8473cb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr",
                "category": "company",
                "datetime": 1786205044,
                "headline": "Eli Lilly and Company Q2 Earnings Call Highlights"
              },
              {
                "id": 141153737,
                "url": "https://finnhub.io/api/news?id=a53b3f047ab14d5de0d882730cf3a123cd1f503af2c85dc6be62a9442592f7cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Can anyone take the top spot away from Eli Lilly in the anti-obesity area?",
                "category": "company",
                "datetime": 1786143000,
                "headline": "Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem"
              },
              {
                "id": 141150981,
                "url": "https://finnhub.io/api/news?id=01b340d0059dd5897227b93517f3fdfead4ba3f07c523cbc6e60306221480045",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Dismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.",
                "category": "company",
                "datetime": 1786132351,
                "headline": "Novo Nordisk Stock Rises After GLP-1 Antitrust Win"
              },
              {
                "id": 141150922,
                "url": "https://finnhub.io/api/news?id=95eb0a6e7ed26b9db1538aa2bc11fd40ec517b5700ac99dccdad84c6f0f2e0c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Berobenatide is one of the keys to Pfizer's future.",
                "category": "company",
                "datetime": 1786132080,
                "headline": "Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound"
              },
              {
                "id": 141150983,
                "url": "https://finnhub.io/api/news?id=dd12bcdfe4ed22cf3954c88504072df39a69214fa699b7fae9f00c2150af3b44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.",
                "category": "company",
                "datetime": 1786127896,
                "headline": "The Two Divergent Paths Priced Into Eli Lilly Stock"
              },
              {
                "id": 141153017,
                "url": "https://finnhub.io/api/news?id=67ccc3c3ad70bef1c4f83f554aa3a6dff52f54d75b3a843a42afc9185766ddb2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2288510391/image_2288510391.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly Q2 2026 surged on Mounjaro/Zepbound; guidance raised to $85–$87B as the pipeline expands. Click here for this latest update.",
                "category": "company",
                "datetime": 1786127357,
                "headline": "Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion"
              },
              {
                "id": 141152423,
                "url": "https://finnhub.io/api/news?id=af72a397d825898b459a1a054ad11e152f22a3d67f610472c2aab599efe41d41",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Weekly dividend activity roundup for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1786125278,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 9"
              },
              {
                "id": 141149426,
                "url": "https://finnhub.io/api/news?id=4e2b8a7d772c899e7acccc9fd973f3f3a5b2ae5a7714cb98fce1f1948962fa7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The S&P 500 and Dow Jones hit highs while the Nasdaq raced above key levels as oil prices and yields fell. Palantir, Cloudflare and SpaceX were big movers amid earings.",
                "category": "company",
                "datetime": 1786120507,
                "headline": "Stock Market Rally Powers Ahead; SpaceX, Palantir, Sandisk Are Key Earnings Movers: Weekly Review"
              },
              {
                "id": 141149427,
                "url": "https://finnhub.io/api/news?id=a38406d5fd339893d46827e488fede0a5bb73db1c2ecef56fc9a476d75886488",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.",
                "category": "company",
                "datetime": 1786120471,
                "headline": "Lilly and Novo Win a Key GLP-1 Antitrust Fight"
              },
              {
                "id": 141144662,
                "url": "https://finnhub.io/api/news?id=c788d44770abb69329f91e62fdaa825f7bcc95adbe6ddc7ed9740f7b0bb37c05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.",
                "category": "company",
                "datetime": 1786116600,
                "headline": "These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks"
              },
              {
                "id": 141146208,
                "url": "https://finnhub.io/api/news?id=c8e51a5c7911f0b7cd49abb0231cf9012f76b82106740c8dedaee2ce40668f6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Which stocks are the best mutual funds buying? Marvell, Apple stock and Santander lead as 14 others also make this monthly screen.",
                "category": "company",
                "datetime": 1786100405,
                "headline": "Apple Among Three Stocks In Voracious Demand. Funds Also Feast On 14 Others."
              },
              {
                "id": 141147599,
                "url": "https://finnhub.io/api/news?id=4a0d5a2aa04ebc63db9125c2de5ecac66308b0af2320c98127255211d0be1c9e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2240821882/image_2240821882.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk A/S gets a Sell rating as profits slide, guidance weakens, and competition rises vs Eli Lilly. Click for this NVO stock update and a look at earnings.",
                "category": "company",
                "datetime": 1786100118,
                "headline": "Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade"
              },
              {
                "id": 141147076,
                "url": "https://finnhub.io/api/news?id=1ec88d1067ceffa064e22daa93479305f5918d913e0386eec7c3a5f5cc194189",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "BMS is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.",
                "category": "company",
                "datetime": 1786094452,
                "headline": "Why Big Pharma is chasing the industry’s most-powerful supercomputer"
              },
              {
                "id": 141147872,
                "url": "https://finnhub.io/api/news?id=cbb2679c72648f9f20eb14efb58ed57960e46f247fb3b2debfd0c6bd3ad6f2e5",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Truist Securities  analyst Robyn Karnauskas   maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1370 to $1376.",
                "category": "company",
                "datetime": 1786094207,
                "headline": "Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1376"
              },
              {
                "id": 141145770,
                "url": "https://finnhub.io/api/news?id=f48593f91ec5b5050f13f5723967e5af0dfe16a3bc52d91b8dc9fefa753d8a08",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In early August 2026, CVS Health reported second-quarter results showing higher sales of US$35,117 million and revenue of US$106.10 billion, alongside net income of US$2,979 million and materially higher earnings per share versus a year earlier. On the same day, CVS Health also raised its 2026 earnings guidance and expanded its GLP-1 weight management offering through a new collaboration with Eli Lilly, underscoring how integrated pharmacy, insurance and care-delivery assets can be combined...",
                "category": "company",
                "datetime": 1786093900,
                "headline": "CVS Health (CVS) Is Down 8.6% After Raising 2026 Guidance And Expanding GLP-1 Tie-Up With Lilly – Has The Bull Case Changed?"
              },
              {
                "id": 141147642,
                "url": "https://finnhub.io/api/news?id=dee3bfaaa26dd1dc193bc2041ad8205d4e968a745c8d4b9c46d64ec0a8da856c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/07/Jim-Cramer.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lilly to acquire AtaiBeckley for $3.8B.",
                "category": "company",
                "datetime": 1786090497,
                "headline": "Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’"
              },
              {
                "id": 141140357,
                "url": "https://finnhub.io/api/news?id=6b7258e8f7f690edee8df4b30816923dff35ec25abc461df5404145045cc9e19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The drugmaker continues to face headwinds.",
                "category": "company",
                "datetime": 1786044000,
                "headline": "Why Is Everyone Talking About Novo Nordisk?"
              },
              {
                "id": 141143949,
                "url": "https://finnhub.io/api/news?id=0d880470a35b5c224053d345c057941e857e5c9faff4b78be6402652f5897ecb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo’s shares have fallen 15% this year, tumbling further this week after guidance missed analysts’ targets.",
                "category": "company",
                "datetime": 1786041487,
                "headline": "Novo Nordisk faces a rough patch"
              },
              {
                "id": 141140175,
                "url": "https://finnhub.io/api/news?id=dac7147c0c2466caa56af37fbbd0d1839dd57e63fac90a6f36585cb8aac53922",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1793099883/image_1793099883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly's stock jumps 5% on strong earnings and raised revenue guidance. Click here to read more about LLY.",
                "category": "company",
                "datetime": 1786038160,
                "headline": "Eli Lilly: Fine Q2 2026 Results, But Alertness Required"
              },
              {
                "id": 141137100,
                "url": "https://finnhub.io/api/news?id=06293378c7a575674b00bff41a1065b72ea81c0f1a2571e0b4b8ba678b8b87a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The real opportunity extends well beyond prescription delivery",
                "category": "company",
                "datetime": 1786036790,
                "headline": "Amazon Takes Bold Step Beyond Retail"
              },
              {
                "id": 141137154,
                "url": "https://finnhub.io/api/news?id=d74187b0396ba6d3834b24ceb2aab5aae8e3b3b3606239426daaeea6e93c0a9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly recently reported that second-quarter 2026 sales rose to about US$23.0 billion with net income of roughly US$7.10 billion, and the company raised its full-year 2026 revenue guidance to US$85.0 billion–US$87.0 billion from US$82.0 billion–US$85.0 billion. Management attributed this step-up in outlook largely to surging demand for its GLP-1 diabetes and weight-loss portfolio, reinforcing how central these products have become to Lilly’s overall earnings power. With Lilly lifting 2026...",
                "category": "company",
                "datetime": 1786036380,
                "headline": "The Bull Case For Eli Lilly (LLY) Could Change Following Raised 2026 Guidance On GLP-1 Demand"
              },
              {
                "id": 141137101,
                "url": "https://finnhub.io/api/news?id=5f1a60fb2d1807d8504c543c56a5908c7e9127818b26c163106b5f3042dba811",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eligible patients can access Wegovy, Zepbound and Foundayo for $50 per month through Amazon Pharmacy.",
                "category": "company",
                "datetime": 1786035853,
                "headline": "Amazon Is Bringing the Weight-Loss Drug Race to Medicare"
              },
              {
                "id": 141137156,
                "url": "https://finnhub.io/api/news?id=2f69e9460fe0aae9ead0dc803c5110b49010b128ce55b4a38234a0a34db793d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.",
                "category": "company",
                "datetime": 1786031340,
                "headline": "ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?"
              },
              {
                "id": 141135355,
                "url": "https://finnhub.io/api/news?id=f2de2082f52dff739c5615a66d343ae67779b0a9098e29e029aef2b173283e53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just posted revenue growth near 50% and crushed earnings estimates, yet the stock barely moved. There is a specific price target for 2027 that Wall Street analysts are only beginning to catch up to, and the math behind it changes the entire valuation story.",
                "category": "company",
                "datetime": 1786030243,
                "headline": "This Will be Eli Lilly’s Price in 2027 And Morgan Stanley Agrees"
              },
              {
                "id": 141135430,
                "url": "https://finnhub.io/api/news?id=b735e9496864246f48a0a419feb3c22ccc7f7d59733d76d0ececdf018ddd5796",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Alzheimer's disease treatment landscape is experiencing a major transformation with the introduction of disease-modifying therapies that target fundamental disease mechanisms, particularly amyloid-β pathology. Among these, LEQEMBI (lecanemab) has become a leading biologic for patients with early-stage Alzheimer's disease, demonstrating its ability to slow cognitive and functional deterioration in biomarker-confirmed individuals. Regulatory approvals across key global markets have strengthene",
                "category": "company",
                "datetime": 1786026660,
                "headline": "The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight"
              },
              {
                "id": 141135431,
                "url": "https://finnhub.io/api/news?id=363e01604d73181ae12b53dfcd2ff26e08a0207b1901e14b7c2e2eae61f13c61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly lifts its 2026 outlook as Foundayo adoption accelerates, Medicare expands obesity access and retatrutide advances toward a 2027 filing.",
                "category": "company",
                "datetime": 1786024800,
                "headline": "LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction"
              },
              {
                "id": 141135574,
                "url": "https://finnhub.io/api/news?id=74783749540edf85cda36b7463044e6afb83926586dbb8833e1cea8019963dbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Amazon’s pharmacy now offers steep discounts for weight-loss drugs, down from as much as $1,500.",
                "category": "company",
                "datetime": 1786024539,
                "headline": "Medicare Made Weight-Loss Drugs $50 A Month—Now Amazon, CVS And Walmart Race To Fill Prescriptions"
              },
              {
                "id": 141142170,
                "url": "https://finnhub.io/api/news?id=0412f5762dd22d3679dd27236ea62af6916d4b48316ed7979a3eb952426a04af",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1280 to $1330.",
                "category": "company",
                "datetime": 1786022408,
                "headline": "Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1330"
              },
              {
                "id": 141136103,
                "url": "https://finnhub.io/api/news?id=47f65fdfa48aa70c57749f5219a46ed9682efbfc0168030744a460c2b125db4b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2216425295/image_2216425295.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk A/S beat Q2 revenue and EPS, raised guidance again, and still dipped. Click for this NVO stock update and see if it is right for you.",
                "category": "company",
                "datetime": 1786019601,
                "headline": "Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore"
              },
              {
                "id": 141135432,
                "url": "https://finnhub.io/api/news?id=19f1e61d2899000132b6fb9c0f6024246d00b4c8a50c9f9bedac28de4fd7192f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk says the company is doubling down on innovation and its weight loss pills as it looks towards its next stage of growth.",
                "category": "company",
                "datetime": 1786019465,
                "headline": "Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company—finding its next blockbuster drug is proving difficult"
              },
              {
                "id": 141134039,
                "url": "https://finnhub.io/api/news?id=7b27e6244f6d63a2ad4040f9002341c2a51edc964794af78befe5e4d0dbcfd0c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders’",
                "category": "company",
                "datetime": 1786017900,
                "headline": "VivoSim Provides Financial and Listing Compliance Update"
              },
              {
                "id": 141133219,
                "url": "https://finnhub.io/api/news?id=41f8e68c6197c582224d0be4bbe4368350f60ecb73f83ea21c1ed91ac787b323",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.",
                "category": "company",
                "datetime": 1786015115,
                "headline": "Eli Lilly raises 2026 outlook again as Q2 soars past estimates"
              },
              {
                "id": 141137157,
                "url": "https://finnhub.io/api/news?id=dd27e6bde8802e356369de66537bb41ebf52d3a911f9c44ba5f7215082bb5025",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.",
                "category": "company",
                "datetime": 1786011597,
                "headline": "Eli Lilly Stock: Analyst Estimates & Ratings"
              },
              {
                "id": 141138969,
                "url": "https://finnhub.io/api/news?id=58899a1927c42e15df02c5160dacfb5c9251b0bc577469cf46b9c21d143ba852",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Novo-Nordisk.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "A Dutch court has banned sales of an unapproved compounded semaglutide nasal spray following a legal victory for Novo Nordisk.",
                "category": "company",
                "datetime": 1786010817,
                "headline": "Novo Nordisk Scores Major Court Win, Dutch Judge Halts Compounded Semaglutide Nasal Spray"
              },
              {
                "id": 141136524,
                "url": "https://finnhub.io/api/news?id=2b23b434c61426ece7bf29e71bc7ae1493122c098e04f005fb11f10c189cff52",
                "image": "https://image.cnbcfm.com/api/v1/image/108261536-1770233397984-Side_by_Side_template.jpg?v=1770233491&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.",
                "category": "company",
                "datetime": 1786009529,
                "headline": "The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings"
              },
              {
                "id": 141133220,
                "url": "https://finnhub.io/api/news?id=903ea0063740f3693287a38c9c857843073c66b3e4096cb8fc00be12f3c71589",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "U.S. stock markets closed mixed on Wednesday halting the August rally.",
                "category": "company",
                "datetime": 1786009500,
                "headline": "Stock Market News for Aug 6, 2026"
              },
              {
                "id": 141138970,
                "url": "https://finnhub.io/api/news?id=ee997d2a77f90d6ca64ef96464712255850b4ad568049d17f796d6905ed0d905",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Weight-Loss--Nutritionist-Consulting-Ove.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Bank of America spends over $250 million yearly on GLP-1 drugs, with CEO Brian Moynihan calling it a smart investment.",
                "category": "company",
                "datetime": 1786008698,
                "headline": "Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'"
              },
              {
                "id": 141142173,
                "url": "https://finnhub.io/api/news?id=8607c7f0a9ff66218e683d6f324e012b12731b68f95ea7d1761eaa9d38ec8182",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1350 to $1410.",
                "category": "company",
                "datetime": 1786004134,
                "headline": "Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1410"
              },
              {
                "id": 141132276,
                "url": "https://finnhub.io/api/news?id=14c845aa763b92b7aa2ddc1e64b3096cd549decf921b9cc44798a7abe99cedc4",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_88_36a319a715.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Wednesday's tape gave back a slice of the multi-day rally as SpaceX's inaugural quarterly print spooked the AI-capex trade, Alphabet lost its most senior AI engineer, and AMD got repriced on a Musk-driven chip switch.",
                "category": "company",
                "datetime": 1786002284,
                "headline": "SpaceX First-Quarter Print And A DeepMind Exit Split The Tape As Records Take A Breather"
              },
              {
                "id": 141135072,
                "url": "https://finnhub.io/api/news?id=5956bea89133f7c75a3c0d3fd2f8fa0876d173ddb7f7ad50762751db7a70ab21",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.aboutamazon.com/news/retail/amazon-pharmacy-glp-1-medicare",
                "category": "company",
                "datetime": 1785996482,
                "headline": "Amazon Pharmacy Start Delivery GLP-1 Medications To Eligible Medicare Patients For $50 Per Month"
              },
              {
                "id": 141135283,
                "url": "https://finnhub.io/api/news?id=61b54d952a72f4dae3b74529ad2a238f7f8fa29b096a0fde8d3c13db7000a809",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Valhalla--Ny--Usa---May-10--2023-Governo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 million New Yorkers.",
                "category": "company",
                "datetime": 1785987665,
                "headline": "Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'"
              },
              {
                "id": 141131618,
                "url": "https://finnhub.io/api/news?id=9d3832f9ccea185202eceaf9032b76f0c20e12d4061d11d248cc0c81baf93742",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5. Analysts expect the company to report quarterly earnings of $6.58 per share, up from $6.31 per share in the year-ago period. The...",
                "category": "company",
                "datetime": 1785987062,
                "headline": "How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings"
              },
              {
                "id": 141136017,
                "url": "https://finnhub.io/api/news?id=b644e060360f14b311a44d39800fa48ededfd477174cead389375c6c540bd8d7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The CNN Money Fear and Greed index showed improvement in market sentiment on Wednesday, while Dow Jones surged to a record high driven by strong earnings.",
                "category": "company",
                "datetime": 1785986108,
                "headline": "Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone"
              },
              {
                "id": 141133221,
                "url": "https://finnhub.io/api/news?id=3417f8c8bb27336375c9340947a66c17360b259da8a403ead5764b58bd72a6b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Moby summary of Eli Lilly and Company's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785982416,
                "headline": "Eli Lilly and Company Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141131798,
                "url": "https://finnhub.io/api/news?id=10b2a3d22dc9833ce1be70887ef88b17d5b092bd3e60d5be9a6e0be49e42592b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly raised 2026 revenue guidance to $85–87B, driven by volume gains despite price declines, and reinforced margin expansion. Read why LLY stock is a Buy.",
                "category": "company",
                "datetime": 1785982171,
                "headline": "Eli Lilly Q2: Strong Results Further Strengthen The Investment Thesis"
              },
              {
                "id": 141130047,
                "url": "https://finnhub.io/api/news?id=9b27a3c7657b224a497f3e1ff2e43602e193206a8c5955bf39ba3cf8eb4cc35c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.",
                "category": "company",
                "datetime": 1785971400,
                "headline": "3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations"
              },
              {
                "id": 141129097,
                "url": "https://finnhub.io/api/news?id=8db7b6882bc727e982f993c485b5d1df8b840684a25c8eba354b215d6812c54b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Demand for the healthcare leader's weight-loss drugs continues to rise.",
                "category": "company",
                "datetime": 1785970410,
                "headline": "Why Eli Lilly Stock Climbed Today"
              },
              {
                "id": 141129113,
                "url": "https://finnhub.io/api/news?id=3d16095d978e92525adbbd38b54041199b8f8835388a49466e61aeee84d2c84e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- Stocks in Asia were poised to ease Thursday as investors digested gains in technology shares while watching for fresh signs of progress toward a deal to reopen the Strait of Hormuz.Most Read from BloombergIran Says Agreement on Hormuz Shipping Reached With OmanSpaceX’s AI Splurge Puts a Damper on First Earnings After IPOTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasit",
                "category": "company",
                "datetime": 1785967610,
                "headline": "Asian Stocks Set for Declines as AI Rally Cools: Markets Wrap"
              },
              {
                "id": 141127315,
                "url": "https://finnhub.io/api/news?id=cf3fa9d377bf144773f8aad98ac4f4f8c91aaa4b11c8c662f00c5df9d5262ee1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Moby summary of Charles River Laboratories International, Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785965850,
                "headline": "Charles River Laboratories International, Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141127414,
                "url": "https://finnhub.io/api/news?id=70b784d51037fc27f530c0693cd7ca54aaa42aced8229c9033418c5edab4fcf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.",
                "category": "company",
                "datetime": 1785964991,
                "headline": "Why PFE Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 141127415,
                "url": "https://finnhub.io/api/news?id=0619ade14b2a1890e8402fd95dc9ca30d7d6ac5efdcc46da1b4834320272b5bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Co (LLY) raises full-year 2026 guidance after Q2 revenue jumps 48%, driven by blockbuster incretin sales and strong international expansion.",
                "category": "company",
                "datetime": 1785964074,
                "headline": "Eli Lilly and Co (LLY) (Q2 2026) Earnings Call Highlights: Revenue Surges 48% on Zepbound and ..."
              },
              {
                "id": 141127416,
                "url": "https://finnhub.io/api/news?id=16d47ac527cc25aeeac0ef319f7cdf465cf06b82a557a04af4da48718bdfe9ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly raised its revenue outlook after Mounjaro and Zepbound generated nearly two-thirds of quarterly sales.",
                "category": "company",
                "datetime": 1785963235,
                "headline": "Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%"
              },
              {
                "id": 141127417,
                "url": "https://finnhub.io/api/news?id=8a291b4825c161edc5c13ce4039297c926b2d077597950a58d1d1376ec858fdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CVS Health  stock fell Wednesday, even after the healthcare giant raised its full-year guidance on the back of second-quarter earnings that handily beat analysts’ projections.  While analysts reacted positively to the earnings announcement, company executives spoke in more detail on an investor call about sources of pressure during the quarter—including from a federal drug pricing program called 340B.  The “incremental angst” on the 2027 outlook is “the clear pressure point for the stock,” said Leerink Partners analyst Michael Cherny in a client note Wednesday afternoon.",
                "category": "company",
                "datetime": 1785962460,
                "headline": "CVS Health Raised Its Outlook, but the Stock Still Fell"
              },
              {
                "id": 141130878,
                "url": "https://finnhub.io/api/news?id=0402786319e4fdd3ec7d886f1d5b3be8d32a3ec8d5d4f55e259a02de52dc9a78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly shares rally on a fresh DTC partnership with CVS Health. A strong Q2 release and impressive future guidance is driving LLY stock higher as well.",
                "category": "company",
                "datetime": 1785959430,
                "headline": "LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs"
              },
              {
                "id": 141125974,
                "url": "https://finnhub.io/api/news?id=c459a2f7de46fc6a834ac3b2bb9cc7e13ce53f1f2b0e244f6bdd50b5191a689c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State",
                "category": "company",
                "datetime": 1785959404,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 141127419,
                "url": "https://finnhub.io/api/news?id=fc27dc80195478d02641ea24c03f6ccd31ec35e73a176fba49a32f5362e170ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Key takeawaysEli Lilly’s second-quarter revenue surged 48 per cent to US$22. 97 billion, beating Wall Street expectations by more than US$2 billion.",
                "category": "company",
                "datetime": 1785959179,
                "headline": "Eli Lilly stock jumps as GLP-1 sales widen Novo lead"
              },
              {
                "id": 141125706,
                "url": "https://finnhub.io/api/news?id=323e5a3f9c5dd535eafdd88ad8552039eeecd9956c9b18925cca11db56bff5ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain.",
                "category": "company",
                "datetime": 1785958260,
                "headline": "Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy."
              },
              {
                "id": 141125707,
                "url": "https://finnhub.io/api/news?id=20f9c29ea9780fc907e693d820e8adab73bd86e692e7bde3c00f6fbd5f35136c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just posted numbers that stunned Wall Street, but the company's own executives admit a single bottleneck could cap how far the GLP-1 juggernaut actually runs, and the next move to break through it is already in motion.",
                "category": "company",
                "datetime": 1785956398,
                "headline": "Eli Lilly’s Weight-Loss Drug Demand Is Nearly Limitless. Here’s What Comes Next for the $1 Trillion Drugmaker"
              },
              {
                "id": 141125708,
                "url": "https://finnhub.io/api/news?id=aa4f6192ff266b0744702ba5908008c62f3442b9eaf167e489de658fd393aa13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Stock Market Today: The Dow Jones index rises Wednesday with word on a Strait of Hormuz deal. AMD stock and SpaceX fall.",
                "category": "company",
                "datetime": 1785956200,
                "headline": "Stock Market Today: Dow Rises, Nasdaq Slides As Tech Stocks Come Under Pressure; Uber Dives (Live Coverage)"
              },
              {
                "id": 141125659,
                "url": "https://finnhub.io/api/news?id=21fb8be31f4b117b356767c095e95409cad32b2d646651192a1c1ccf094f1c80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SpaceX stock sinks after earnings. AMD drops after Elon Musk says his AI and space company will exclusively use Nvidia chips.",
                "category": "company",
                "datetime": 1785955380,
                "headline": "SpaceX, Alphabet, Nvidia, Micron, AMD, Uber, CVS, Lilly, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141125710,
                "url": "https://finnhub.io/api/news?id=908443464c6dac93d7d144bad74f909237b4d1ce507acfbe554ffe8dd66c08d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.",
                "category": "company",
                "datetime": 1785952740,
                "headline": "Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?"
              },
              {
                "id": 141127331,
                "url": "https://finnhub.io/api/news?id=9fe0a702f3a7e3925db399c2f56e6e9ab519a141d5adfb869e364ffdf3179a3d",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly and Company (LLY) Q2 2026 Earnings Call August 5, 2026 10:00 AM EDTCompany ParticipantsMike Czapar - Director of Investor RelationsDavid Ricks -...",
                "category": "company",
                "datetime": 1785952200,
                "headline": "Eli Lilly and Company (LLY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141124158,
                "url": "https://finnhub.io/api/news?id=834d3108befef54bff0c51720f24625dd831717162daf0b8f1c1146a75e40da4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.",
                "category": "company",
                "datetime": 1785952140,
                "headline": "Novo Nordisk Is Exiting a ‘Rough Patch,’ CFO Says. Earnings Prove It."
              },
              {
                "id": 141124159,
                "url": "https://finnhub.io/api/news?id=4395029b748f9c1773424c0bf90efdad8a55a4105535e31630585af3b828c074",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-cons",
                "category": "company",
                "datetime": 1785951879,
                "headline": "CVS, Eli Lilly Forge Partnership on Improved GLP-1 Access; Companies Top Second-Quarter Views"
              },
              {
                "id": 141122813,
                "url": "https://finnhub.io/api/news?id=0ff64425d56d5ca138cecf01ace2d13937fb2f41f11acbfe50b37f2dc67c00e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly  posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications, though one glaring question hung over the print.  The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet.  Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.",
                "category": "company",
                "datetime": 1785951780,
                "headline": "Eli Lilly Stock: The One Question in Otherwise Perfect Earnings and What It Means for Shares"
              },
              {
                "id": 141124161,
                "url": "https://finnhub.io/api/news?id=59cac24a44287e15270a423ae9fcdc1b7050b90eecf09e7918eddc9a1509305c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and th",
                "category": "company",
                "datetime": 1785951758,
                "headline": "Sector Update: Healthcare Stocks Advance Wednesday Afternoon"
              },
              {
                "id": 141125711,
                "url": "https://finnhub.io/api/news?id=86654da613505d37a72deed55f1f4b51cbc7a004fc7b41b9e6fd5f1e19cb0c5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.",
                "category": "company",
                "datetime": 1785951300,
                "headline": "INSP's 28.1% Past-Month Rally Raises a Key Question for Investors"
              },
              {
                "id": 141121105,
                "url": "https://finnhub.io/api/news?id=a3c02fdab82ec37292ab8838306b16cb77615cde3ea467ff3a798250d5b04bfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Stock Market Today: The Dow Jones index rises Wednesday after surprise jobs data. AMD stock and SpaceX plunge on earnings.",
                "category": "company",
                "datetime": 1785950886,
                "headline": "Stock Market Today: Dow Rises After Surprise Jobs Data; AMD, SpaceX Plunge On Earnings (Live Coverage)"
              },
              {
                "id": 141122814,
                "url": "https://finnhub.io/api/news?id=f20e7a2dc06254658a41134e30d368a56ecc0f48db7eba719532e87e7cbbd867",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CVS Health  stock was falling Wednesday morning after the healthcare giant raised its full-year guidance on the back of second-quarter earnings that handily beat analysts’ projections.  The 6% decline in share price reversed a 3.9% rise during premarket trading.  While analysts reacted positively to the earnings announcement, company executives spoke in more detail on an investor call about sources of pressure during the quarter—including from a federal drug pricing program called 340B.",
                "category": "company",
                "datetime": 1785950580,
                "headline": "CVS Health Raises Earnings Outlook, but the Stock Is Falling"
              },
              {
                "id": 141124164,
                "url": "https://finnhub.io/api/news?id=c6a7af1543dceadb1b730393e9d7fd6db41b46c3138b8a37f8991928c792eb6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "On Aug. 5, 2026, new highs across major indexes reflect renewed confidence in global trade as investor confidence starts to return.",
                "category": "company",
                "datetime": 1785949331,
                "headline": "Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning Markets"
              },
              {
                "id": 141123271,
                "url": "https://finnhub.io/api/news?id=41596b07c037fe81a6963035041969d9a5305c9b2c7c1ef2d76aaea6efc80395",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1785947701,
                "headline": "Top S&P500 movers in Wednesday's session"
              },
              {
                "id": 141126383,
                "url": "https://finnhub.io/api/news?id=caa6b6837d07405532b603bb862219d6794152718d01854baae4e6509008ba79",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "2026-08-05. The following slide deck was published by Eli Lilly and Company in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1785947507,
                "headline": "Eli Lilly and Company 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141124165,
                "url": "https://finnhub.io/api/news?id=f69bf26c9d421d18cd8e6c53091619803f7d45773a322443c448922bbebc8fe2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Set against the backdrop of a mixed Q2, Novo is eyeing bolt-ons in favour of transformative acquisitions.",
                "category": "company",
                "datetime": 1785946945,
                "headline": "Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says"
              },
              {
                "id": 141124166,
                "url": "https://finnhub.io/api/news?id=2b58a2b70a614fd7eb95675fb60fa6b620b990c4eed234103bd5771f1f2ae0fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.",
                "category": "company",
                "datetime": 1785946020,
                "headline": "LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance Raised"
              },
              {
                "id": 141126014,
                "url": "https://finnhub.io/api/news?id=4ca154ba64515bee5ba02348b2bcfc96c4b3f716d2aaef53bf1dd2abbbbb6145",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217256698/image_2217256698.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.",
                "category": "company",
                "datetime": 1785945929,
                "headline": "Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan"
              },
              {
                "id": 141122822,
                "url": "https://finnhub.io/api/news?id=66feb67d01e4d70e0094ed3a397369ee81fb7e771b1a676824a3bc9007bf3596",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SpaceX stock sinks after earnings. AMD drops after Elon Musk says his AI and space company will exclusively use Nvidia chips.",
                "category": "company",
                "datetime": 1785945720,
                "headline": "SpaceX, Nvidia, Micron, AMD, Uber, CVS, Lilly, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141124168,
                "url": "https://finnhub.io/api/news?id=fe18b167af707b0fc63be22f01d9e144cb609bf75d08bf2943724d668be19325",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "US equities were mixed and crude oil eased in late-morning trading Wednesday as investors remained h",
                "category": "company",
                "datetime": 1785945478,
                "headline": "Top Midday Stories: SpaceX Shares Fall After Inaugural Results; AMD Drops Despite Strong Q2 EPS, Revenue"
              },
              {
                "id": 141124169,
                "url": "https://finnhub.io/api/news?id=72c45d59d23cf8a80168bb098a63031a9d5d3b7a5025fb2a8250cc243fa24256",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.",
                "category": "company",
                "datetime": 1785945300,
                "headline": "AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure"
              },
              {
                "id": 141136525,
                "url": "https://finnhub.io/api/news?id=8c979e837b07ad3b806248538c4681f6ed87c24f740e411e580064af414b04f2",
                "image": "https://image.cnbcfm.com/api/v1/image/108345554-17859563161785956314-47596913118-1080pnbcnews.jpg?v=1785956315&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Evan Seigerman, BMO, joins 'Power Lunch' to discuss the recent excitement in the healthcare space, economic pressure in the space and much more.",
                "category": "company",
                "datetime": 1785944566,
                "headline": "Continue to like Eli Lilly due to its better obesity franchise, says BMO's Evan Seigerman"
              },
              {
                "id": 141122269,
                "url": "https://finnhub.io/api/news?id=8299593b2535219dc21e8aa943661e86e6fcc479cf9b0b64eefd0462dd9202fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Wegovy maker raised its outlook, but investors focused on pricing pressure, a pill sales miss and another pipeline stumble.",
                "category": "company",
                "datetime": 1785942369,
                "headline": "Novo Nordisk Swallows the Bitter Pill"
              },
              {
                "id": 141124170,
                "url": "https://finnhub.io/api/news?id=03a2bc0898c99d3044ff5ff8aa38241e509893ae0cce5938dafa73efca4374d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "July Private Payrolls Well Below Expectations .",
                "category": "company",
                "datetime": 1785942360,
                "headline": "July Private Payrolls Well Below Expectations"
              },
              {
                "id": 141121867,
                "url": "https://finnhub.io/api/news?id=6beb908ae12813dfd98a52eb52bb2db4a5234cb5fae50594bf2bc304a6172d38",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Wondering which stocks are making significant price gaps? Explore the S&P500 index on Wednesday to find the gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1785940501,
                "headline": "Which S&P500 stocks are gapping on Wednesday?"
              },
              {
                "id": 141122365,
                "url": "https://finnhub.io/api/news?id=f6f3af235fa649b2b6406ff363a525cc8f9e5d4580756ff2f674571db4e9f064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Today's ADP private-sector payrolls came in below the +75K forecast and less than half the downwardly revised +95K from June.",
                "category": "company",
                "datetime": 1785940380,
                "headline": "ADP Cools to +44K, Earnings Show Beats from DIS, LLY & More"
              },
              {
                "id": 141124772,
                "url": "https://finnhub.io/api/news?id=1db0cc6302bebe93b61e5eb9d2a4357679405616901a47c4a140ddf7ad352f6e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Digital-Gold-Price-Stock-Market-Trading-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool inflation fears.",
                "category": "company",
                "datetime": 1785939260,
                "headline": "Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today"
              },
              {
                "id": 141121498,
                "url": "https://finnhub.io/api/news?id=fa6da8c7216714237df7ad2060c3a28e7dc5cec383d3d2fe089ac3c85ce9e88b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors have plenty of reasons to be uncertain right now. But that has not wholly shaken companies' faith in their ability to deliver strong earnings growth this year.",
                "category": "company",
                "datetime": 1785938765,
                "headline": "The companies defying macro uncertainty and raising guidance: AlphaCheck"
              },
              {
                "id": 141122367,
                "url": "https://finnhub.io/api/news?id=f336fb91e510731a060df6de8643ca133da8ab0855b6c73bee066cf722a50ada",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
                "category": "company",
                "datetime": 1785938402,
                "headline": "Lilly (LLY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141122368,
                "url": "https://finnhub.io/api/news?id=01215da94211ff9f8add795b36434a18c87530866859daaed8e2f22883778d89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) rose more than 5% in pre-market trading on Wednesday after the pharmaceutical company increased its full-year revenue guidance, supported by continued strong demand for its blockbuster diabetes and weight-loss treatments. The revised outlook outweighed an earnings-per-share miss for the second quarter, as investors focused on accelerating sales growth and improved profitability expectations.",
                "category": "company",
                "datetime": 1785938007,
                "headline": "Eli Lilly shares climb after stronger revenue outlook driven by obesity drugs"
              },
              {
                "id": 141122369,
                "url": "https://finnhub.io/api/news?id=7fe8a08ae9eaee84286801b530cf48f84bbd2a39464813e523060d52c043e36e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly raised its 2026 sales forecast as its GLP-1 drugs outperformed expectations in Q2.",
                "category": "company",
                "datetime": 1785938005,
                "headline": "Eli Lilly stock soars on strong demand for weight-loss drugs"
              },
              {
                "id": 141121502,
                "url": "https://finnhub.io/api/news?id=783c24647d487f174faa5946263b1ee40b64c2e2ce980f43986b7f57ae0e7bf6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The S&P 500 climbed 0.6% on Wednesday, while SpaceX stock slumped more than 10% on its first quarterly report since going public",
                "category": "company",
                "datetime": 1785937885,
                "headline": "S&P 500 hits record high on Disney, Eli Lilly earnings"
              },
              {
                "id": 141121167,
                "url": "https://finnhub.io/api/news?id=ea000d0b1029e84094307260142c0bfe06abcbe8a88620f488f13748bf491903",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Outside the U.S., volume climbed 113% against a 36% drop in realized prices",
                "category": "company",
                "datetime": 1785937852,
                "headline": "Eli Lilly Stock Rises as Volume Growth Outruns Falling Prices"
              },
              {
                "id": 141122371,
                "url": "https://finnhub.io/api/news?id=f1bae86f09197f8a949bee4c943a59ca1f157b55184f6236e8fc079189627904",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may not be what defines the company a decade from now. A billion-dollar bet on artificial intelligence could change everything.",
                "category": "company",
                "datetime": 1785937830,
                "headline": "GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future"
              },
              {
                "id": 141121168,
                "url": "https://finnhub.io/api/news?id=ea79e6e6e6f5251c705b42afd34d2b119c54233d81521870e5b3c73f2edae4fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Zepbound and Mounjaro helped drive a major earnings beat and a higher sales outlook.",
                "category": "company",
                "datetime": 1785937499,
                "headline": "Eli Lilly's Weight-Loss Engine Is Still Accelerating"
              },
              {
                "id": 141121169,
                "url": "https://finnhub.io/api/news?id=357248f6c816a8c4935536dbc9f9b4c7e2843492cb9c61954d4f1474a65ba43d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Co (NYSE:LLY) shares rose nearly 7% in early trading Wednesday after the drugmaker reported second quarter results that topped Wall Street revenue expectations and raised its full-year 2026 revenue outlook, with strong demand for its Mounjaro and Zepbound weight-loss and diabetes...",
                "category": "company",
                "datetime": 1785937020,
                "headline": "Eli Lilly shares rise on revenue beat, raised outlook"
              },
              {
                "id": 141121170,
                "url": "https://finnhub.io/api/news?id=624629d327dd2e48c8d6a65d8cb75362021d21df0152e86138df22ee3f92ca0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly’s second-quarter revenue jumped 48% and comfortably beat Wall Street estimates, driven primarily by strong demand for its blockbuster weight loss drugs Mounjaro and Zepbound.",
                "category": "company",
                "datetime": 1785936225,
                "headline": "Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’"
              },
              {
                "id": 141121171,
                "url": "https://finnhub.io/api/news?id=6b314df4eb17491efdef22e18e6b345e4c915a6d0d3b02842a9eab27a9fc8913",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "STORY: :: Novo Nordisk'''Right now, the market isn't convinced that Novo Nordisk pipeline of experimental drugs is robust enough to fight against Lilly.'':: How is Novo Nordisk future proofing as investors worry about pipeline?:: August 5, 2026:: Maggie Fick, European Pharma Industry Correspondent ''The drugmaker on Tuesday raised its full year profit and sales outlook, but investors are less focused on the numbers. They did look at the weaker than expected sales for its new Wegovy pill, and they're more focused on what the answer that the company has is to this question of the expirations of the patents for the company's key drugs. '''''So the name of the game now really is the medicines that Novo Nordisk is testing right now in trials. And also on Tuesday, Novo reported a trial failure for one of its next generation obesity drugs, obesity and diabetes drugs, CagriSema, and we think that's part of the reason that shares fell on these announcements.'':: What is CEO Mike Doustdar's response?:: Novo Nordisk''So Mike Doustdar acknowledged these recent trials setbacks, but he argued that they don't change the company's strategy. He says the answer is to move faster in research. He's been at the helm of the company now for a year. And he said one of the important steps he took was to combine research and development under one executive, and that that is helping that department move faster with trials. And he continues to say that failures are part of the pharmaceutical industry, that, trials are run with risks and so this is not unusual and they just have to keep moving. He said that it's important for Novo to stick to its strategy of bolt-on acquisitions to complement its own research and development. And he stressed that a transformational acquisition, a big merger, is not something on his agenda and that's for companies that have big problems.''",
                "category": "company",
                "datetime": 1785935967,
                "headline": "Novo Nordisk looks to future proof as investors worry over pipeline"
              },
              {
                "id": 141124825,
                "url": "https://finnhub.io/api/news?id=3f7300c88330590328f9b1d2e113f9e80e78fc69d4dc99368ff614696d984e92",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Nvidia-office-building--Taipei--Taiwan.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "\n\n\n\nExtreme Positive Sentiment\n\n\n\nPlease click here for an enlarged chart of SPDR S&P 500 ETF Trust (NYSE:SPY) which represents the benchmark stock market index S&P 500 (SPX).\n\n\n\nNote the following:\n\n\n\n\n The",
                "category": "company",
                "datetime": 1785935846,
                "headline": "SpaceX Chooses Nvidia; Short Squeeze Drives Market Rally, But Extreme Positive Sentiment Flashes Warning"
              },
              {
                "id": 141121172,
                "url": "https://finnhub.io/api/news?id=93d55f11d053620ba39190ef317ca6473731a387d5958ee903b04dfd9bde0b2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad",
                "category": "company",
                "datetime": 1785935415,
                "headline": "Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Corporate Earnings, Hormuz Reopening Hopes"
              },
              {
                "id": 141121173,
                "url": "https://finnhub.io/api/news?id=7e7839c70b306cf300a4fd5f1290664b8f1491fbdeac41cc59c4db441ca929cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock jumped Wednesday on a solid beat-and-raise thanks to its GLP-1 drugs, treatments for diabetes and obesity.",
                "category": "company",
                "datetime": 1785934600,
                "headline": "Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop"
              },
              {
                "id": 141121174,
                "url": "https://finnhub.io/api/news?id=da686b542c2f6d53f3b0ab9a6cde608c86ce6a85a68911abb5d9460819dd28e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1785934188,
                "headline": "Update: Potential Strait of Hormuz Deal Buoys US Equity Futures Pre-Bell"
              },
              {
                "id": 141122372,
                "url": "https://finnhub.io/api/news?id=8ab57fa9716dd0346791b1a26f4816f085568fea2a20628a17592035d0bb1395",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- In Brazilian supermarkets, a beloved national snack — pao de queijo — is being sidelined by yogurt.Most Read from BloombergTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealSpaceX’s AI Splurge Puts Damper on Debut Earnings After IPOChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersBeer Dynasty Families Sell €731 Million Stake in AB InBevTaco Bell Met With Michigan on Parasite Weeks Before RecallGrocers in South America’s largest country are reworking aisle",
                "category": "company",
                "datetime": 1785933900,
                "headline": "How GLP-1s Reshape Grocery Aisles in Fast-Growing Market for Weight-Loss Drugs"
              },
              {
                "id": 141121175,
                "url": "https://finnhub.io/api/news?id=e88b692b5b4ab660820016f7aa02c18a8208d36b3059527b16e938c0230c0acd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales.",
                "category": "company",
                "datetime": 1785933429,
                "headline": "Mounjaro sales double this year as obesity drug boom prevails, says maker"
              },
              {
                "id": 141120805,
                "url": "https://finnhub.io/api/news?id=c7bd52b475fb75372a286906251e0256b3c53c47c1e6c7d37dbd30857513f8f1",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.",
                "category": "company",
                "datetime": 1785933301,
                "headline": "Wondering what's happening in today's S&P500  pre-market session?"
              },
              {
                "id": 141122373,
                "url": "https://finnhub.io/api/news?id=2e22fa215fed0073c346fa6cfaacb9bbe9389f21d506c975928ed7963693c06d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.",
                "category": "company",
                "datetime": 1785933120,
                "headline": "Novo Nordisk Stock Bounces Back After Surprise Earnings Report"
              },
              {
                "id": 141123139,
                "url": "https://finnhub.io/api/news?id=a8630d27e6bd33fddd58234a6636409f49ad989f587f4109e62bbbe323bf56cd",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255462840/image_2255462840.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly and Company beats earnings, boosts 2026 guidance on GLP-1 drugs Mounjaro/Zepbound. Click here to read my most recent analysis of the LLY stock.",
                "category": "company",
                "datetime": 1785932880,
                "headline": "Eli Lilly Q2 Earnings Review: Breath-Taking Results Mean Higher Ceiling On Stock Price Target"
              },
              {
                "id": 141121159,
                "url": "https://finnhub.io/api/news?id=9b551f8bb877a85423f6fceb03498cc8388b0eab31bdd64dfd15d0287c125d25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "FEATURE  Stock futures rose Wednesday and both the and the were poised to again set record highs.   SpaceX dropped 11% after Elon Musk’s rockets, telecom, and artificial-intelligence company beat analysts’ second-quarter earnings targets but reported higher capital expenditure than Wall Street was expecting.",
                "category": "company",
                "datetime": 1785932280,
                "headline": "SpaceX, Nvidia, AMD, Eli Lilly, Uber, CVS, Disney, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141121177,
                "url": "https://finnhub.io/api/news?id=23e6ddf098968bb77ad4c266e778419394fc5af585454c4207229c455f8f2bdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The benchmark US stock measures were trending higher in Wednesday's premarket activity amid growing",
                "category": "company",
                "datetime": 1785932158,
                "headline": "Stocks Rise Pre-Bell Amid Growing Hopes for Hormuz Deal; Traders Await More Corporate Earnings"
              },
              {
                "id": 141121178,
                "url": "https://finnhub.io/api/news?id=7ef1ae290e19ecf53ce1451c281d92930206ac4f9c54c1cff1e4d4a0985b85da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) delivered earnings and revenue surprises of +39.43% and +13.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785932105,
                "headline": "Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates"
              },
              {
                "id": 141121179,
                "url": "https://finnhub.io/api/news?id=30d6db5057d42db0330e108e560de644c730965efa729884f0202e4d13690a15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "News of the day for Aug. 5, 2026",
                "category": "company",
                "datetime": 1785931883,
                "headline": "5 Things to Know Before the Stock Market Opens on Wednesday"
              },
              {
                "id": 141121180,
                "url": "https://finnhub.io/api/news?id=3311c2f00176979b9f5c5138869991dc277499b8c45df4143e6b66c3ea940584",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "8.30am: ADP jobs softens US private-sector hiring slowed to 44,000 jobs in July from 98,000 in June, missing the 65,000 forecast and pointing to cooling labour demand. The softer reading could give the Federal Reserve more scope to cut rates, weighing on Treasury yields and the dollar...",
                "category": "company",
                "datetime": 1785931800,
                "headline": "Dow Jones and S&P 500 set to notch new highs despite AMD and SpaceX falls"
              },
              {
                "id": 141126657,
                "url": "https://finnhub.io/api/news?id=102821957d81bb6ecefd074516db590840004b773fb1251f461daf4fc9b1a344",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Eli-Lilly.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.",
                "category": "company",
                "datetime": 1785931562,
                "headline": "Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion"
              },
              {
                "id": 141121181,
                "url": "https://finnhub.io/api/news?id=607dec4ca1b085d0802705d38e7dc1f8d3b21b11d1d66e7e5022805309cc50e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Novo Nordisk, the world’s two largest makers of weight-loss and diabetes drugs, raised their full-year forecasts on the back of...",
                "category": "company",
                "datetime": 1785931301,
                "headline": "Eli Lilly and Novo Nordisk raise profit outlook as demand for weight-loss drugs soars"
              },
              {
                "id": 141123661,
                "url": "https://finnhub.io/api/news?id=0d20bf865ac861c6b76c7a5e11df5c0ed2ba0ba1a35dccf114a31fd3c941c9a8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Luminar-Technologies-Inc-NASDAQLAZR.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Stocks mixed as Nasdaq falls 100 points, Dow rises .79%. Eli Lilly beats earnings estimates, Digital Turbine surges 43%, oil down .4%, gold up 2.5%",
                "category": "company",
                "datetime": 1785931097,
                "headline": "Nasdaq Falls Over 100 Points; Eli Lilly Shares Gain On Upbeat Earnings"
              },
              {
                "id": 141121182,
                "url": "https://finnhub.io/api/news?id=7c4ce0f908d266e0a4970e774a4b67966e9d4e4b1d62bc117b581f4d3460416d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CVS Health  stock jumped on Wednesday after the healthcare giant raised its full-year guidance on the back of second-quarter earnings that handily beat analysts’ projections.  For the second quarter, CVS Health posted adjusted earnings of $2.58 a share.  Analysts polled by FactSet were looking for $1.85 a share.",
                "category": "company",
                "datetime": 1785930360,
                "headline": "CVS Health Stock Climbs on Earnings Outlook Hike and Lilly Weight-Loss Drug Partnership"
              },
              {
                "id": 141121183,
                "url": "https://finnhub.io/api/news?id=8c3ea13f0320c8cfe4a98f05016822bb4d18ee7d40adaa2bbf617d6e2b3c56de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly  posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications.  The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet.  Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.",
                "category": "company",
                "datetime": 1785930000,
                "headline": "Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly Doubles"
              },
              {
                "id": 141122166,
                "url": "https://finnhub.io/api/news?id=d4ec070ea553c491664f2efb7b5c45a749a34a20f74172020bfa94e89e0e765d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk Q2 results: obesity drug growth (Wegovy pill) offsets pricing pressure. Shares fell 6%, but DCF suggests 25% upside. Click for more on NVO stock.",
                "category": "company",
                "datetime": 1785929790,
                "headline": "Novo Nordisk: Opportunistically Adding To A Long-Term Winner (Q2 Review)"
              },
              {
                "id": 141120279,
                "url": "https://finnhub.io/api/news?id=e01b36e27ba9c0e2ac002b778cabf52c44ebf4b9e3d46c5d8cbb35499584308c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- Eli Lilly shares jumped more than 5% in premarket trading Wednesday after the U.S. pharma giant raised its annual revenue guidance amid strong demand for its popular weight-loss and diabetes drugs.",
                "category": "company",
                "datetime": 1785929664,
                "headline": "Eli Lilly shares pop as weight-loss drug demand fuels guidance hike"
              },
              {
                "id": 141120280,
                "url": "https://finnhub.io/api/news?id=3810005cc5ccf9991b09aa8c4e749ecee37bdbc5e653646c30ad46af52da6f42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates",
                "category": "company",
                "datetime": 1785929538,
                "headline": "Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast"
              },
              {
                "id": 141126659,
                "url": "https://finnhub.io/api/news?id=7e824d5fc0498be0330b6a1b6a4f72e935b57b1fd79519120c19db556ab88f7e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Chandler--Arizona---April-08-2023cvs-Hea.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown.",
                "category": "company",
                "datetime": 1785928740,
                "headline": "CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal"
              },
              {
                "id": 141120281,
                "url": "https://finnhub.io/api/news?id=58dfabf5f7af002f0732ad56dad186c29b6f822a3e53e90defbc09c7a4af8ee2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CVS beat Wall Street expectations by a wide margin in the second quarter and raised its full-year profit forecast to as much as $8.10 per share",
                "category": "company",
                "datetime": 1785928512,
                "headline": "CVS Health Q2 2026 earnings beat, Eli Lilly weight loss drug deal"
              },
              {
                "id": 141120285,
                "url": "https://finnhub.io/api/news?id=576355aedb6054103db654b08daf20745d83dd6aa5b71729852a8db41f208396",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.",
                "category": "company",
                "datetime": 1785928308,
                "headline": "CVS shares jump on earnings beat, raised full-year guidance"
              },
              {
                "id": 141120282,
                "url": "https://finnhub.io/api/news?id=57fb7e76bddf5eb4ce11fe46cec2783bc7ee76ac2c02a5add12ee99cb52752a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The addition of Foundayo (orforglipron) provides participants with an FDA-approved, injection-free, GLP-1 treatment for people living with excess weight within a structured personalized care platform NEW YORK CITY, NY / ACCESS Newswire / August 5, ...",
                "category": "company",
                "datetime": 1785927600,
                "headline": "Onsera Health Strengthens Cardiometabolic Care Delivery with Eli Lilly's(R) Oral GLP-1 Foundayo(R)"
              },
              {
                "id": 141120283,
                "url": "https://finnhub.io/api/news?id=ef1f97456389598acf57e255fdc61ef89a56ca3789a267195ddc4bfb84b0684c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785926984,
                "headline": "Eli Lilly (NYSE:LLY) Beats Expectations in Strong Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations"
              },
              {
                "id": 141120284,
                "url": "https://finnhub.io/api/news?id=0a9c8a071d9e74ee9e6a34033c02e563ac8b66db8b77e7353027d1f8d260fbb6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2026 and provided updated 2026 financial guidance.",
                "category": "company",
                "datetime": 1785926700,
                "headline": "Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress"
              },
              {
                "id": 141126660,
                "url": "https://finnhub.io/api/news?id=538fa580f9741343e01ecb3b744a4e6f5905d962451536d047dcd5e8fc31015f",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "-Conference Call ",
                "category": "company",
                "datetime": 1785925564,
                "headline": "Eli Lilly CFO Says Expects Global Rollout Of Foundayo In All Major Markets In 2027"
              },
              {
                "id": 141120286,
                "url": "https://finnhub.io/api/news?id=929390d508df1918042148d3135c588fa170cbc68ae07a72befdd063e0556902",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CVS Health® (NYSE: CVS) today announced a revamp of its weight management program, making it easier for eligible adults to access clinical care, navigate medication costs and get ongoing support for GLP-1 therapy.",
                "category": "company",
                "datetime": 1785925500,
                "headline": "CVS Health enhances its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications"
              },
              {
                "id": 141126661,
                "url": "https://finnhub.io/api/news?id=cb3ef6cfc60753090d01c4e85a7c9033069f8f67e77da545d7fec74f39eddc55",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "- Conference Call",
                "category": "company",
                "datetime": 1785924946,
                "headline": "Eli Lilly CFO Says Injectable GLP-1 Drugs Remain Key Growth Driver, Account For Three Out Of Four New Patient Starts"
              },
              {
                "id": 141123540,
                "url": "https://finnhub.io/api/news?id=1157658eda8f40e815beec177ad93294f3586328cce2c276153ab2f5ff5664fb",
                "image": "https://image.cnbcfm.com/api/v1/image/108345251-17859367881785936786-47592402976-1080pnbcnews.jpg?v=1785936787&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Watch the opening bell for the New York Stock Exchange, the Nasdaq and Cboe from August 5, 2026.",
                "category": "company",
                "datetime": 1785923059,
                "headline": "Opening Bell: August 5, 2026"
              },
              {
                "id": 141121973,
                "url": "https://finnhub.io/api/news?id=6b5f81855f363feff13020cf56c2bf744b82737b0ddb1b34c2a20a608fb00ce7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Wall-Street.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Dow and S&P 500 indices hit new all-time highs, Treasury Sec. Bessent says Iran deal may reopen Strait of Hormuz.",
                "category": "company",
                "datetime": 1785919267,
                "headline": "Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)"
              },
              {
                "id": 141120683,
                "url": "https://finnhub.io/api/news?id=6c25c75a7fae1004dfd69a1846b65a34f516c21f7c915cb4cf1fa37d965080e9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/530591555/image_530591555.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "WisdomTree BioRevolution Fund delivered a dramatic acceleration in performance over S&P 500 Index, thereby drawing attention to this particular investment theme. Read more here.",
                "category": "company",
                "datetime": 1785918000,
                "headline": "The BioRevolution Has Accelerated"
              },
              {
                "id": 141123541,
                "url": "https://finnhub.io/api/news?id=f96e6f36af3bc35c7c20016dbefacda525601d75d2965624beb608ab61a7ba5c",
                "image": "https://image.cnbcfm.com/api/v1/image/108345135-17859270381785927035-47590223630-1080pnbcnews.jpg?v=1785927037&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Joe Kernen reports on the company's quarterly earnings results.",
                "category": "company",
                "datetime": 1785912886,
                "headline": "Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge"
              },
              {
                "id": 141126663,
                "url": "https://finnhub.io/api/news?id=89b0788405da33f3e5a5caf04f2cc4262423621cd054672320adf44a877783bc",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) narrows FY2026 Adj EPS guidance from $35.50-$37.00 to $35.50-$35.60 vs $34.20 analyst estimate. Raises FY2026 sales outlook from $82.000 billion-$85.000 billion to $85.000 billion-$87.000 billion vs",
                "category": "company",
                "datetime": 1785912380,
                "headline": "Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est"
              },
              {
                "id": 141126664,
                "url": "https://finnhub.io/api/news?id=77c7efcd35bc988403c0b7252f7cbf7bbc6fbdd9ca514abdb616bca78fe62704",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) reported quarterly earnings of $8.38 per share which beat the analyst consensus estimate of $6.01 by 39.43 percent. This is a 32.81 percent increase over earnings of $6.31 per share from the same",
                "category": "company",
                "datetime": 1785912355,
                "headline": "Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate"
              },
              {
                "id": 141125527,
                "url": "https://finnhub.io/api/news?id=c78b593c886378d2e8dbd934f656f7b237dca8776a47b308ee652114a9f38654",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options.New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients an additional access point at",
                "category": "company",
                "datetime": 1785911349,
                "headline": "CVS Health Retools Its Weight Management Program To Make It Easier For Eligible Adults To Access Clinical Care, Navigate Medication Costs And Get Ongoing Support For GLP-1 Therapy"
              },
              {
                "id": 141118733,
                "url": "https://finnhub.io/api/news?id=3a82f58b2a6b940cf475eb00ca4ac2ce85027434559cf67dd1a0edfc59aae3e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) stock is back in focus after the FDA granted Breakthrough Therapy designation to its investigational drug olomorasib for KRAS G12C-mutant advanced pancreatic cancer, highlighting an expanding oncology effort. See our latest analysis for Eli Lilly. Eli Lilly’s share price has eased recently, with a 7 day share price return down 8.60% and a 30 day share price return down 8.09%. This is even though the 1 year total shareholder return sits at 46.69% and the 5 year total...",
                "category": "company",
                "datetime": 1785906790,
                "headline": "Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Is The Stock Still Cheap?"
              },
              {
                "id": 141121978,
                "url": "https://finnhub.io/api/news?id=ae6d1188804b6d253c834c7c9b82adf78b74dd89c2f03caa04b170ef908fd531",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Stock-S-And-P-500-Index-Fund-Symbol-Is-O.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Polymarket traders see more upside after the S&P 500 hit a record high on strong earnings and hopes for a U.S.-Iran deal.",
                "category": "company",
                "datetime": 1785903697,
                "headline": "Stock Market: Will S&P 500 Open Up or Down Today?"
              },
              {
                "id": 141121812,
                "url": "https://finnhub.io/api/news?id=ab36f0006b4f08f9fe29bd5dc14f11f221663766c04467702f86f16c92c25d68",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Market sentiment improves, Dow Jones jumps 900 points to record high. Crude oil prices fall on potential deal to reopen Strait of Hormuz.",
                "category": "company",
                "datetime": 1785898931,
                "headline": "Dow Jumps Over 900 Points As Crude Oil Falls: Investor Sentiment Improves Further, Fear Index Moves To ‘Greed’ Zone"
              },
              {
                "id": 141123542,
                "url": "https://finnhub.io/api/news?id=87309e96ee0c8cef2ecb4988e9b97aab9fa8c6edbb3644be1ec21fba510274ad",
                "image": "https://image.cnbcfm.com/api/v1/image/108314048-1780081680407-gettyimages-2278066776-REAGAN_ECONOMIC_FORUM.jpeg?v=1784653024&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "U.S. Treasury Secretary Scott Bessent told CNBC that Iran and the U.S. could reach a deal to open the Strait of Hormuz by Wednesday.",
                "category": "company",
                "datetime": 1785897980,
                "headline": "CNBC Daily Open: Markets rally on hopes of Iran-U.S. Strait of Hormuz deal"
              },
              {
                "id": 141121979,
                "url": "https://finnhub.io/api/news?id=d5b7c009c320a8fb3cdfabbfaf848c3598ba576d08b8d60ab19f988ce6a66b99",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Tech-CEOs-Briefed-On-Taiwan.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "U.S. stock futures up, Eli Lilly, AMD, Disney, SpaceX and SanDisk expected to release earnings. SpaceX beats estimates, shares down 7.5%.",
                "category": "company",
                "datetime": 1785896522,
                "headline": "AMD, Walt Disney And 3 Stocks To Watch Heading Into Wednesday"
              },
              {
                "id": 141123543,
                "url": "https://finnhub.io/api/news?id=de56a4bdf6ff7be19ee23013cd6174eb964ac638c1c7071591234df0ccf8f684",
                "image": "https://image.cnbcfm.com/api/v1/image/108283569-17745429042026-03-26t163346z_145582249_rc2dckaqvbrc_rtrmadp_0_novo-nordisk.jpeg?v=1774542953&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.",
                "category": "company",
                "datetime": 1785895891,
                "headline": "Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%"
              },
              {
                "id": 141116439,
                "url": "https://finnhub.io/api/news?id=85620f1d6cecfb8951af3f9b92120d5a83604f8036308bc173bd79ccd3113827",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Dow and S&P 500 hit new highs while the Nasdaq powered higher again. SpaceX, AMD and Arista led earnings movers late.",
                "category": "company",
                "datetime": 1785887706,
                "headline": "Dow Jones Futures Rise; SpaceX, AMD, Arista Lead Earnings Movers After S&P 500 Jumps To High"
              },
              {
                "id": 141114845,
                "url": "https://finnhub.io/api/news?id=951aad7d19dd20f351277a51092af5cd5591b142138ba348833e264eb6fbc64b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Dow and S&P 500 hit new highs while the Nasdaq powered higher again. SpaceX, AMD and Arista led earnings movers late.",
                "category": "company",
                "datetime": 1785879996,
                "headline": "Dow Jones Futures: SpaceX, AMD, Arista Lead Earnings Movers After S&P 500 Jumps To High"
              },
              {
                "id": 141113185,
                "url": "https://finnhub.io/api/news?id=ffe8f821463a343289a11f64068bcee41cc91dca55356f4a3d50ffb074e8f0f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them.",
                "category": "company",
                "datetime": 1785871390,
                "headline": "The $85 Billion Consolation Prize For JNJ Shareholders"
              },
              {
                "id": 141126669,
                "url": "https://finnhub.io/api/news?id=45b7fbb72eeca25ade3314d953a5cd4a5f303f0b2819d6a18f8286acc3c8bb48",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 6.87% on an annualized basis producing an average annual return of 16.31%. Currently, Eli Lilly has a market capitalization of $1.01 trillion.",
                "category": "company",
                "datetime": 1785870928,
                "headline": "$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141113186,
                "url": "https://finnhub.io/api/news?id=1d31e96915e4d959df1cba8f787901697fd39e9ce1f068b2a56dc114ece4f5fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.",
                "category": "company",
                "datetime": 1785867532,
                "headline": "Novo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats Up"
              },
              {
                "id": 141113187,
                "url": "https://finnhub.io/api/news?id=5283a66cae90903f1d6dd6d104a422fec01538896fdaaff5ec250ebe56d8b2ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.",
                "category": "company",
                "datetime": 1785867360,
                "headline": "Novo Nordisk Raises Earnings Guidance. The Stock Sinks."
              },
              {
                "id": 141113188,
                "url": "https://finnhub.io/api/news?id=7206b7759f2f4565c6b1a57bf62905e49ad5e3ce3357816a15d768411657652c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly plans to file for FDA approval in the first quarter of next year",
                "category": "company",
                "datetime": 1785866426,
                "headline": "Lilly Opens Pre-Approval Access to Its Next Obesity Drug"
              },
              {
                "id": 141123544,
                "url": "https://finnhub.io/api/news?id=0ad5460d2a3d00fea29f5c039c77732887d23bd37fd5a47f2ad60264193e5d11",
                "image": "https://image.cnbcfm.com/api/v1/image/108344921-17858803021785880299-47580011457-1080pnbcnews.jpg?v=1785880301&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "John Flavin, Portal Innovations, joins 'Fast Money' to talk what to expect from pharma earnings.",
                "category": "company",
                "datetime": 1785866249,
                "headline": "Portal Innovations CEO John Flavin: Novo Nordisk is undervalued"
              },
              {
                "id": 141114652,
                "url": "https://finnhub.io/api/news?id=3bfe372f566f7074b1ea3c7cc30656ee668ec79585d8bdd583cb8d1a97b6c090",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/04/Earnings-Season-Written-In-Search-Bar-Wi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Earnings coming Wed with varying volatility levels. Benzinga Pro selected list incl. relatively muted setups to double-digit swings. Top pick Eli Lilly.",
                "category": "company",
                "datetime": 1785857472,
                "headline": "Eli Lilly Could Swing $65.9 Billion After Earnings"
              },
              {
                "id": 141109945,
                "url": "https://finnhub.io/api/news?id=051e2b85a54d63e0649526172248b346f31ae1a45c1cf6ba0a309512b0b0dd59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]",
                "category": "company",
                "datetime": 1785856506,
                "headline": "Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market?"
              },
              {
                "id": 141111550,
                "url": "https://finnhub.io/api/news?id=de33b8a0123d2b292054ba1f29716341249c010c55f9d5ee0e321353a5057f28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212125572/image_2212125572.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "OPKO Health's Q2 results: IP revenue surged on Nicoya deal and FY2026 guidance rose. Click for this OPK stock update.",
                "category": "company",
                "datetime": 1785851748,
                "headline": "OPKO Health: Mazdutide And MDX-2201 Could Change Everything"
              },
              {
                "id": 141108540,
                "url": "https://finnhub.io/api/news?id=1a9dd163ca1b9ab6353601339e8c4fa171db7ebfd9f4132424609847340d3d67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Adyen, the global financial technology platform of choice for leading businesses, today announced it will help facilitate payment services for prescribed patients accessing Lilly's FDA-approved medicines and free home delivery through LillyDirect.",
                "category": "company",
                "datetime": 1785848400,
                "headline": "Adyen to Provide Payment Technology Services for LillyDirect"
              },
              {
                "id": 141108541,
                "url": "https://finnhub.io/api/news?id=943f8682ffaf9d23419b0388706b276057bc0399df776df98a146079ea228e02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand.",
                "category": "company",
                "datetime": 1785847980,
                "headline": "Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway."
              },
              {
                "id": 141108542,
                "url": "https://finnhub.io/api/news?id=23e28aa6d38abdc63a2e588ab39710290070a8284b370297ac6ba9cd846ec526",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company’s investigational FAK inhibitor narmafotinib in combination with Lilly’s late‑stage investigational next generation KRAS inhibitor olomorasibThe collaboration is underpinned by narmafotinib’s growing base of clinical evidence and a strong scientific rationale that FAK activation is a key driver of resistance to KRAS G12C inhibitorsThe collaboration further ex",
                "category": "company",
                "datetime": 1785847500,
                "headline": "Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer"
              },
              {
                "id": 141108543,
                "url": "https://finnhub.io/api/news?id=6c35b7878481e63ea1dedfd5a62b8fa9987f897c4f38a74d2f7715e5e7033cd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785845104,
                "headline": "Pfizer (PFE) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141108544,
                "url": "https://finnhub.io/api/news?id=3ba73eb480f565d3b222d2e26e21c31875414361f708858d97bc10009ca620bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.",
                "category": "company",
                "datetime": 1785844380,
                "headline": "AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open"
              },
              {
                "id": 141107627,
                "url": "https://finnhub.io/api/news?id=4453440e15320b6c4f4fd1f510317ae6798277c904f1a88d29554629842e1dc7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think.",
                "category": "company",
                "datetime": 1785844200,
                "headline": "Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?"
              },
              {
                "id": 141108545,
                "url": "https://finnhub.io/api/news?id=5cace6b1818a89425fa15c5d46a7541c08b7ac98c564ae01b451830fd7012bc3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker’s stock could potentially approach last month’s highs following the results.",
                "category": "company",
                "datetime": 1785842100,
                "headline": "Here’s How Much Traders See Eli Lilly Stock Moving After Earnings"
              },
              {
                "id": 141107875,
                "url": "https://finnhub.io/api/news?id=9e012f62b1fb29e0685464b4dc8c218668bf7dd232dc8e96486b97019d07400a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevApple’s New CEO Taps Retired Hardware Executive for Management TeamTaco Bell Met With Michigan on Parasite Weeks Before RecallMamdani Dismisses Business Leaders Advising NYC’s Mayor’s FundS&P 5",
                "category": "company",
                "datetime": 1785841205,
                "headline": "Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally"
              },
              {
                "id": 141107720,
                "url": "https://finnhub.io/api/news?id=66f652dbeb9015072a7b9617d4f486815b3c3ad8ef6c701df94bdea4a3bf1bd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience",
                "category": "company",
                "datetime": 1785841200,
                "headline": "iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer"
              },
              {
                "id": 141107073,
                "url": "https://finnhub.io/api/news?id=c80a13bab04e9a5ea561e8049df88e3a59350d488699dbe6057fede94485bdf5",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_o_neill_9796d922cc.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly passes the CANSLIM growth screen with strong EPS and sales growth, high relative strength, but poor setup timing.",
                "category": "company",
                "datetime": 1785837050,
                "headline": "Eli Lilly (NYSE:LLY) Stands Out as a High-Growth Momentum Leader"
              },
              {
                "id": 141108419,
                "url": "https://finnhub.io/api/news?id=4886ad9f03b09da7279f69a49c8985a0598f2ff3ec690a423ee3ea4802c71af6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2235939814/image_2235939814.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "The 4-Factor Dividend Growth Strategy, inspired by SCHD, targets high-quality, growth-oriented dividend stocks using four key metrics for selection.",
                "category": "company",
                "datetime": 1785836819,
                "headline": "SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For August 2026"
              },
              {
                "id": 141108547,
                "url": "https://finnhub.io/api/news?id=49652a4559e9583895c1ac2fa9994fe217a035f76c4c0e0af13b5670710e7dbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.",
                "category": "company",
                "datetime": 1785834174,
                "headline": "Three potential takeover targets in psychedelics"
              },
              {
                "id": 141106141,
                "url": "https://finnhub.io/api/news?id=dbf4b6019f91f02858a1ece648ddae5789111607280907eb8c2c8f7b58dbb7e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.",
                "category": "company",
                "datetime": 1785821400,
                "headline": "More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not"
              },
              {
                "id": 141105562,
                "url": "https://finnhub.io/api/news?id=c771aa68805d01528d37a1c03f77dce73d16ee26ab8eb69d1cfb94afb6f826af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF) has signed a clinical collaboration agreement with Eli Lilly and Company to evaluate its lead drug narmafotinib alongside Lilly’s next-generation KRAS G12C inhibitor olomorasib in patients with advanced non-small cell lung cancer (NSCLC). The...",
                "category": "company",
                "datetime": 1785812760,
                "headline": "Amplia Therapeutics partners with Lilly on lung cancer combination trial"
              },
              {
                "id": 141104931,
                "url": "https://finnhub.io/api/news?id=4cf59adf1b2f42f10f102aa96b5df13b20d7146faf86e12581504965c65d53fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting",
                "category": "company",
                "datetime": 1785801830,
                "headline": "Inspire Medical Systems Q2 Earnings Call Highlights"
              },
              {
                "id": 141104215,
                "url": "https://finnhub.io/api/news?id=f90be4844bbfd3be905a623ee6e1e0773889b20041c5133207617d9f83f6a119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.",
                "category": "company",
                "datetime": 1785798877,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off"
              },
              {
                "id": 141102900,
                "url": "https://finnhub.io/api/news?id=464078ab83ed3ac59a21f80135cada4cf9fff4fc02acfdf1db4a7e9565544198",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The FDA granted Breakthrough Therapy designation to Eli Lilly's olomorasib as a monotherapy for KRAS G12C-mutant advanced pancreatic cancer. This is the second Breakthrough Therapy designation for olomorasib, which targets a patient group with limited treatment options. Ratio Therapeutics raised US$70 million in a Series C round that included participation from Eli Lilly. Eli Lilly, traded as NYSE:LLY, has long been known for its focus on oncology, diabetes and immunology. The latest...",
                "category": "company",
                "datetime": 1785791319,
                "headline": "Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Backs $70 Million Raise"
              },
              {
                "id": 141102901,
                "url": "https://finnhub.io/api/news?id=d4dad4b699c25939294901b37ea777c978aeb76e6fceb2ae6fa35fdbcd0e2d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.",
                "category": "company",
                "datetime": 1785791142,
                "headline": "AbbVie's Growth Now Leans On A Single Molecule"
              },
              {
                "id": 141102902,
                "url": "https://finnhub.io/api/news?id=105ae9569d10d8f32f5b3a20404384a8ab44971fdad5e287d175cab107a3488c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Updates with market moves at the end of the day, and other changes, if any.) The Dow Jones Indus",
                "category": "company",
                "datetime": 1785789447,
                "headline": "Update: Dow Hits Record High as Oil Prices Slide on Iran Deal Hopes"
              },
              {
                "id": 141101914,
                "url": "https://finnhub.io/api/news?id=9b521e747f577fb2d6f6c2fe0f7fac7e1534075c43b7eaed035edca227e594fb",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1785783901,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141100579,
                "url": "https://finnhub.io/api/news?id=da1ddc0c292bad7c6ad06572bb50752463234a2ffca12103a3663ae056853d51",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion.",
                "category": "company",
                "datetime": 1785779350,
                "headline": "Is Eli Lilly Stock Running out of Steam?"
              },
              {
                "id": 141100723,
                "url": "https://finnhub.io/api/news?id=ac1b8d45986a4ccfaa224fa6feaa4d1c492d1c044d4bf321333f9e9d5d767e82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Early data could widen Lilly's growth story beyond incretins",
                "category": "company",
                "datetime": 1785779258,
                "headline": "Eli Lilly's Latest Cancer Win Comes With a Big Caveat"
              },
              {
                "id": 141100724,
                "url": "https://finnhub.io/api/news?id=f634952b11666bd4bd4148f5e4ec1439f862d29cf0053e4980e09d93bba623ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Updates with latest market prices and developments.) US stocks climbed intraday as oil prices fe",
                "category": "company",
                "datetime": 1785778272,
                "headline": "Update: Equities Rise Intraday, Oil Slides Amid Middle East Deal Optimism"
              },
              {
                "id": 141102903,
                "url": "https://finnhub.io/api/news?id=1616416f52964b33626780df4bbf688e25cb5403a3309b1f71b9e4583bd1f513",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?",
                "category": "company",
                "datetime": 1785778200,
                "headline": "Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?"
              },
              {
                "id": 141100589,
                "url": "https://finnhub.io/api/news?id=378f2753fc4a1a9d91890a317c2a1ace57b55170bf75fff60c2e091727067ac6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.",
                "category": "company",
                "datetime": 1785777458,
                "headline": "Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”"
              },
              {
                "id": 141100726,
                "url": "https://finnhub.io/api/news?id=480a048633dcb40e0db419afb82fa69d4efd3e5b6a9cb642a01ad5a37dacc672",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.",
                "category": "company",
                "datetime": 1785775209,
                "headline": "Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test"
              },
              {
                "id": 141100727,
                "url": "https://finnhub.io/api/news?id=93beca83add4b02ad8b271b7b1ba0242659fa4ae9be591f4bd91c8198b9827db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.",
                "category": "company",
                "datetime": 1785773653,
                "headline": "Stocks mixed as AstraZeneca merger talk dents FTSE 100"
              },
              {
                "id": 141100568,
                "url": "https://finnhub.io/api/news?id=3c052da3472b159c80521c8aaacc6bb6fb9e6cdb6802410d5b78a0c3426c7cfe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "S&P 500 companies' second-quarter earnings growth has eased from a week ago as a sharp slowdown in p",
                "category": "company",
                "datetime": 1785772924,
                "headline": "S&P 500 Quarterly Profit Growth Eases Amid Sharp Tech Slowdown, Oppenheimer Says"
              },
              {
                "id": 141100729,
                "url": "https://finnhub.io/api/news?id=2f7ca19d1e293883a7d79bd9ed8cd6efdd291037094840e9c94316e7395cb646",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.",
                "category": "company",
                "datetime": 1785771780,
                "headline": "Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?"
              },
              {
                "id": 141100730,
                "url": "https://finnhub.io/api/news?id=25e5e0fb81d2067824eea7fc6292e203f6a3d5a7663d562967c15729e12c00c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early sales.",
                "category": "company",
                "datetime": 1785770220,
                "headline": "Will Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold?"
              },
              {
                "id": 141104216,
                "url": "https://finnhub.io/api/news?id=d77b4af73a0ae6b155f2e7af6fd9eb9d1432425df71bb6ac044b62a72ae183e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]",
                "category": "company",
                "datetime": 1785768954,
                "headline": "Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison"
              },
              {
                "id": 141099110,
                "url": "https://finnhub.io/api/news?id=ca669bedc7b6aa4850e9cb825fa1ca87a4cbbf71718598089bb22fc42ba2f6ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.",
                "category": "company",
                "datetime": 1785767340,
                "headline": "Bristol Myers Squibb Stock Jumps on Report of $400 Billion Merger Talks With Big Rival"
              },
              {
                "id": 141100732,
                "url": "https://finnhub.io/api/news?id=b8e9934d63187f557118facd3e7c79eb83f223804de57844f22b83011155e975",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Lilly’s drug for advanced pancreatic cancer.",
                "category": "company",
                "datetime": 1785764631,
                "headline": "Eli Lilly’s Olomorasib Secures Second FDA Breakthrough Designation For Cancer Therapy – Retail Expects LLY Stock To Hit Record High Soon"
              },
              {
                "id": 141102053,
                "url": "https://finnhub.io/api/news?id=67586e144f5eb86102cb965608c9bb05a1db438c2eac3a013ba54efebedaaf46",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1785764116,
                "headline": "6 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141098881,
                "url": "https://finnhub.io/api/news?id=c045b52d10b19b63dd4462e91b4df548edbe99c78ed4c6599088d28927cd36c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock has delivered very strong gains over the past five years, yet the latest valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a sizeable gap below the current price while the broader scorecard still leans expensive. Eli Lilly has returned about 357.2% over five years, which puts extra focus on whether the current price already reflects investors' optimism. The FDA's Breakthrough Therapy designation for olomorasib can...",
                "category": "company",
                "datetime": 1785762558,
                "headline": "Eli Lilly (LLY) Stock Looks Below Fair Value On Cash Flow"
              },
              {
                "id": 141098882,
                "url": "https://finnhub.io/api/news?id=1b7f67d905968762fe06abb5ed353b12be96ae19f775222c482ad3e6e92ed4ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.",
                "category": "company",
                "datetime": 1785762265,
                "headline": "Earnings live updates: Marriott stock falls as Middle East drags, Trump brothers-backed American Bitcoin swings to loss"
              },
              {
                "id": 141098883,
                "url": "https://finnhub.io/api/news?id=b46de72b5e232979612974ad806909a54b55d5c4d3a86936432f3aa3470eadc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1785761749,
                "headline": "Update: Middle East Diplomacy Optimism, Oil Price Decline Lift US Equity Futures Pre-Bell"
              },
              {
                "id": 141098884,
                "url": "https://finnhub.io/api/news?id=015764f465a109d28c3bae83c7179033e4550a032bc8d1df7615a77638a8adf6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "US equity futures were higher pre-bell Monday as the US moved toward diplomacy in its war with Iran",
                "category": "company",
                "datetime": 1785757983,
                "headline": "Middle East Diplomacy Optimism, Oil Price Decline Lift US Equity Futures Pre-Bell"
              },
              {
                "id": 141098885,
                "url": "https://finnhub.io/api/news?id=9980afa07aca3d2b0358a869f45d28825ee24364c626358500296572e4123f4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The benchmark US stock measures were pointing higher before the opening bell Monday as President Don",
                "category": "company",
                "datetime": 1785757880,
                "headline": "Stocks Rise Pre-Bell as Trump Calls Off Planned Iran Strikes; Labor Market Data, Corporate Earnings on Deck"
              },
              {
                "id": 141098886,
                "url": "https://finnhub.io/api/news?id=959b6a402444ba827d62cfaffb1971837db6ea44661f7c6cd2a5154b36374c1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib is an investigational, potent and highly selective next-generation inhibitor of KRAS G12C. Olomorasib was previously grant",
                "category": "company",
                "datetime": 1785757500,
                "headline": "Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer"
              },
              {
                "id": 141098887,
                "url": "https://finnhub.io/api/news?id=48d0b35462c58b56f76fb282a857a48a7324ea7d8a8bec1032ce82a8f07a63bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the",
                "category": "company",
                "datetime": 1785755481,
                "headline": "Falling Oil Boosts Wall Street Pre-Bell; Asia Mixed, Europe Up"
              },
              {
                "id": 141098888,
                "url": "https://finnhub.io/api/news?id=f76d0e33e499d72b1e400a7953869eb6295ae6e9871950c6b0fb3999a90a2ff6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SpaceX reports second-quarter results, new GLP-1s are coming, latest ‘Spider-Man’ pushes Hollywood toward record haul, and more news to start your day.",
                "category": "company",
                "datetime": 1785753900,
                "headline": "Stock Markets Can’t Rely on Tech to Power Gains Anymore"
              },
              {
                "id": 141097853,
                "url": "https://finnhub.io/api/news?id=118b3314695d2346f9ab79a7e3bdb02cfcc70f0eb463a093ee3375c7662428b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The funding will advance its ATLAS trial, assessing lead candidate [Ac-225]RTX-2358, a FAP-targeted radiotherapeutic for advanced sarcomas.",
                "category": "company",
                "datetime": 1785750358,
                "headline": "Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy"
              },
              {
                "id": 141098487,
                "url": "https://finnhub.io/api/news?id=6b73378c560e32fe7ffbd26b50d5e3dfd7aff3077c2e1645bc2f089acb954fce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Microsoft, Amazon and Alphabet's have been highlighted in this Earnings Preview article.",
                "category": "company",
                "datetime": 1785747360,
                "headline": "Microsoft, Amazon and Alphabet's are part of Zacks Earnings Preview"
              },
              {
                "id": 141100371,
                "url": "https://finnhub.io/api/news?id=a95de6099030a228faf4c471e2773bbb3f956c530d9e452f00e4d31337ecaeb0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Earnings-Season-Written-In-Search-Bar-Wi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings reports.",
                "category": "company",
                "datetime": 1785746059,
                "headline": "Eli Lilly Could Swing Over $76 Billion In Value After Earnings"
              },
              {
                "id": 141097854,
                "url": "https://finnhub.io/api/news?id=f899db4064e0a15c1e37c16a16226b3c4cad84b1ec1e5f217dcc31f842155777",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "With American alcohol consumption near historic lows, Boston Beer Company is fighting an uphill battle.",
                "category": "company",
                "datetime": 1785744000,
                "headline": "Bear of the Day: Boston Beer (SAM)"
              },
              {
                "id": 141095661,
                "url": "https://finnhub.io/api/news?id=e521cd63ab7c7c629cbacd51d71cc8083035c3b4fc3eccc8093450f495edcab7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "President Trump said he's holding off on massive new Iran attacks. SpaceX, AMD, Sandisk, Lilly earnings loom as market rally attempt begins.",
                "category": "company",
                "datetime": 1785714580,
                "headline": "Dow Jones Futures Rise, Oil Prices Dive As Trump Shifts On Iran; SpaceX, AMD, Sandisk, Eli Lilly Earnings Loom"
              },
              {
                "id": 141095662,
                "url": "https://finnhub.io/api/news?id=07534dd6f49fc8e73bc45a6dfa316217bd3c256c1ba00247c52b0a2e273139f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Key Takeaways; Cannabis Sector Vireo Growth to Acquire Planet 13 in Landmark All-Stock Deal SNDL Completed Parallel Asset Acquisition, Expanding its U.S. Medical Cannabis Footprint Tilray Posted Record FY2026 Revenue as Cannabis Sales Rose and Losses Narrowed Key Takeaways; Psychedelic Sector Eli Lilly’s $3.8 Billion Deal to Acquire AtaiBeckley Signals a Major Push into Psychedelic-Inspired […]",
                "category": "company",
                "datetime": 1785709588,
                "headline": "Weekly Roundup on the Cannabis Sector & Psychedelic Sector"
              },
              {
                "id": 141094788,
                "url": "https://finnhub.io/api/news?id=3f8727d0954fad695567eb16f68ec5e7fe7d41f5b4a4c5ebe2490ea343301f49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In another heavy earnings week, we’ll also see reports from McDonald’s, Disney, Uber, Devon Energy, and more.",
                "category": "company",
                "datetime": 1785693600,
                "headline": "Jobs Report, Palantir, AMD, SpaceX, Eli Lilly, and More to Watch This Week"
              },
              {
                "id": 141095663,
                "url": "https://finnhub.io/api/news?id=76b29023b205127f17abac539d6fe371910583b31adc20a06953b4913097cc1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.",
                "category": "company",
                "datetime": 1785690002,
                "headline": "Earnings, PMI and Other Key Things to Watch this Week"
              },
              {
                "id": 141093361,
                "url": "https://finnhub.io/api/news?id=9598b716b4a3ca680e2f0775898cfa28c372ceee758a15137f93f30eae0f996a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "President Trump said he's holding off on massive new Iran attacks. SpaceX, AMD, Sandisk, Lilly earnings loom as market rally attempt begins.",
                "category": "company",
                "datetime": 1785677572,
                "headline": "Dow Jones Futures Due As Trump Calls Off Iran Attacks; SpaceX, AMD, Sandisk, Eli Lilly Earnings Loom"
              },
              {
                "id": 141093362,
                "url": "https://finnhub.io/api/news?id=a98e6df10e104faf7155343fe9b53fe7915c20ec32da40b9f3ac30de2eac8e76",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.",
                "category": "company",
                "datetime": 1785672934,
                "headline": "Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141093532,
                "url": "https://finnhub.io/api/news?id=029774edf61c80fb92e2cc87f454bb45e5fbaeb0b947089442175e57684b2ede",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2240144272/image_2240144272.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Discover August 2026’s Top 25 high-growth dividend stocks trading below intrinsic value, with yield, growth, and return forecasts—research the list now.",
                "category": "company",
                "datetime": 1785666049,
                "headline": "Top 25 High-Growth Dividend Stocks For August 2026"
              },
              {
                "id": 141092794,
                "url": "https://finnhub.io/api/news?id=6a9e8400d7341f9a25b45a9c8952c859d2f92fe0d0bc5c12a951ccc2c8e93cbf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2280702393/image_2280702393.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Wall Street catalyst week preview: July jobs report, SpaceX debut earnings, and AI semiconductor spending.",
                "category": "company",
                "datetime": 1785655144,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141091020,
                "url": "https://finnhub.io/api/news?id=ef70e07437fc55e34162edf0b7750dff563ec23b7f0259e98ca3b25df6cfb679",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "President Trump said he's holding off on massive new Iran attacks. SpaceX, AMD, Sandisk, Lilly earnings loom as market rally attempt begins.",
                "category": "company",
                "datetime": 1785640019,
                "headline": "Dow Jones Futures: Trump Calls Off Iran Attacks; SpaceX, AMD, Sandisk, Eli Lilly Earnings Loom"
              },
              {
                "id": 141089523,
                "url": "https://finnhub.io/api/news?id=bf2c7f502a67c236817c88cb1eb8074c249b1ed37e7faf281d2f18e03f7e038e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk stock has slipped over the past year and is down 36.4% over three years, yet the valuation checks still lean supportive, which sets up a different picture from what the share price alone might suggest. Recent headlines around the ZEUS trial setback and legal action against Eli Lilly have sharpened the focus on whether the current price fairly reflects the risks and opportunities. The share price decline of 36.4% over three years points to a period where investors who bought...",
                "category": "company",
                "datetime": 1785618679,
                "headline": "Novo Nordisk (NVO) Stock Looks Below Fair Value Despite Recent Setbacks"
              },
              {
                "id": 141089497,
                "url": "https://finnhub.io/api/news?id=5e0e414275d37967b0aeabb3dadba2900012395868b7036c1c46e3d6a51495d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "And it will likely be the first company in the sector to get there.",
                "category": "company",
                "datetime": 1785616620,
                "headline": "Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031"
              },
              {
                "id": 141087655,
                "url": "https://finnhub.io/api/news?id=9de17a5f3bdcc68bc05d4cf666a8e11bd0e6515b1992fd4959b95b7838d3aa1b",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Wall Street Week Ahead: key earnings (SpaceX, AMD), IPOs, dividends & macro data (PMIs, jobs). Read here for more details.",
                "category": "company",
                "datetime": 1785583800,
                "headline": "SpaceX's First Earnings Post IPO"
              },
              {
                "id": 141084273,
                "url": "https://finnhub.io/api/news?id=6d380be3698e24a208ac107c07942be73cb7d1addd080ff48936dbc6d56d4045",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.",
                "category": "company",
                "datetime": 1785545545,
                "headline": "NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court"
              },
              {
                "id": 141084260,
                "url": "https://finnhub.io/api/news?id=fa1367ee99c5a62836fc6159271047c1c5bd1a98c088765393fb3afb2c541a49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Companies that have reported in the Q2 cycle are offering encouraging reads on order trends, margin resilience, and full-year demand. This fundamental health is filtering directly into analyst models, driving a steady stream of upward revisions for Q3 and beyond.",
                "category": "company",
                "datetime": 1785540240,
                "headline": "Beyond the Mag 7: Rising Q3 Estimates Signal a Market-Wide Earnings Expansion"
              },
              {
                "id": 141082577,
                "url": "https://finnhub.io/api/news?id=1a94eb2201e3abbd3656b840f134ff2b4adcbb19f38c716c72b5b9b7f5d47385",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock market bounced but hasn't taken this step while a key risk is growing. SpaceX, AMD, Sandisk, Eli Lilly earnings loom.",
                "category": "company",
                "datetime": 1785531188,
                "headline": "Dow Jones Futures: Market Rebounds, Now Watch For This; SpaceX, AMD, Sandisk, Eli Lilly Earnings Loom"
              },
              {
                "id": 141082578,
                "url": "https://finnhub.io/api/news?id=6ff1c6433ed8b8d6e02cd41e0a26dca24afb5ed41e5629974eb002260af31a59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk and Eli Lilly, the firms behind Ozemic, Wegovy and Zepbound, faced selling pressure on Friday.",
                "category": "company",
                "datetime": 1785528948,
                "headline": "Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said."
              },
              {
                "id": 141081484,
                "url": "https://finnhub.io/api/news?id=ada25948b94b8a4e97d04c0823114da3b18707a0bfecf93bb9313c1e11a679d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Most of what Cramer says on the \"Mad Money\" Lightning Round is fast and directional. Occasionally, he drops a framework that reveals how he actually thinks about investing, not just trading. When a caller asked about Eli Lilly (LLY) on Tuesday, July 28, Cramer did not give a buy or sell, according ...",
                "category": "company",
                "datetime": 1785523618,
                "headline": "Jim Cramer says one popular stock is meant to be owned, not traded"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 248,
            "discarded_article_count": 224
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.1,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日3日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 2723516.6666666665,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 3300610,
              "avg_vol_20": 2763015,
              "avg_vol_30": 2723516.6666666665,
              "range_pct_10": 0.1055905012229037,
              "range_pct_20": 0.1055905012229037,
              "range_pct_30": 0.114973552423045,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.211892712240914,
              "dist_to_20d_high": 0.014313384491114784,
              "down_shrink_days": 1,
              "breakout_level_20d": 1238,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.9183894817338828
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.5,
            "details": {
              "atrPct": 3.4133804516984516,
              "turnoverUsdM": 1863.3493016095497,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.LLY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 1136.9744,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 6.8,
            "take_profit_price": 1320.5244,
            "target_multiplier": 1.9,
            "technical_strength": 1.9,
            "take_profit_percent": 8.2
          },
          "positionPoints": 1.5,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2011552940018437,
          "stopLossPercent": 6.826760903396903,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.LLY",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 41.6528,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.41
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "強勢區",
      "score": 10,
      "value": 91.78
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0052
    },
    "kdj": {
      "d": 64.46,
      "j": 101.31,
      "k": 76.75,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 48.59
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 20061185,
      "recentSlope": -52051.5,
      "previousSlope": 331230
    },
    "rsi": 55.92,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 1116.6616,
      "position": "SAR喺價下",
      "distancePct": 8.49,
      "previousTrend": "上升"
    },
    "ma50": 1164.6152,
    "macd": {
      "macd": 11.851190272252552,
      "trend": "強烈看漲",
      "signal": 7.6239401709003864,
      "histogram": 4.2272501013521655
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 1175.7629,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 6
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.56,
      "score": 2,
      "avgVolume": 2711754,
      "currentVolume": 1526985
    },
    "derived": {
      "ma20": 1179.9655,
      "ma50": 1164.6152,
      "prevClose": 1215.02,
      "avgVolume10": 3236219,
      "avgVolume20": 2711754,
      "changePercent": 0.43,
      "avgVolumeForScore": 2711754
    },
    "ma_cross": {
      "ma20": 1179.9655,
      "ma50": 1164.6152,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 1176.783,
      "prevMa50": 1161.8536,
      "spreadPct": 1.32,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 1117.237,
      "upper": 1242.694,
      "position": "上半部"
    },
    "rsi_short": 84.66,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.56
    }
  }
}

{
  "close": 1220.28,
  "volume": 1526985,
  "changePercent": 0.43
}